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ABSTRACT: Metabolism of xenobiotics remains a central
challenge for the discovery and development of drugs,
cosmetics, nutritional supplements, and agrochemicals. Meta-
bolic transformations are frequently related to the incidence of
toxic effects that may result from the emergence of reactive
species, the systemic accumulation of metabolites, or by
induction of metabolic pathways. Experimental investigation of
the metabolism of small organic molecules is particularly
resource demanding; hence, computational methods are of
considerable interest to complement experimental approaches.
This review provides a broad overview of structure- and ligand-
based computational methods for the prediction of xenobiotic
metabolism. Current computational approaches to address
xenobiotic metabolism are discussed from three major perspectives: (i) prediction of sites of metabolism (SOMs), (ii)
elucidation of potential metabolites and their chemical structures, and (iii) prediction of direct and indirect effects of xenobiotics
on metabolizing enzymes, where the focus is on the cytochrome P450 (CYP) superfamily of enzymes, the cardinal xenobiotics
metabolizing enzymes. For each of these domains, a variety of approaches and their applications are systematically reviewed,
including expert systems, data mining approaches, quantitative structure−activity relationships (QSARs), and machine learning-
based methods, pharmacophore-based algorithms, shape-focused techniques, molecular interaction fields (MIFs), reactivity-
focused techniques, protein−ligand docking, molecular dynamics (MD) simulations, and combinations of methods. Predictive
metabolism is a developing area, and there is still enormous potential for improvement. However, it is clear that the combination
of rapidly increasing amounts of available ligand- and structure-related experimental data (in particular, quantitative data) with
novel and diverse simulation and modeling approaches is accelerating the development of effective tools for prediction of in vivo
metabolism, which is reflected by the diverse and comprehensive data sources and methods for metabolism prediction reviewed
here. This review attempts to survey the range and scope of computational methods applied to metabolism prediction and also to
compare and contrast their applicability and performance.
■ INTRODUCTION
In the discovery and development of new medicines, attrition
rates are still very significant, despite the comprehensive mea-
sures taken by the chemical and pharmaceutical industry to
lower the risk of failure. In pharmaceuticals, toxicity is a major
contributor to the withdrawal of new drugs and often the
underlying biological mechanism of toxicity is related to metabo-
lism. Metabolic liability is not only a safety concern for drugs
but is also highly relevant to a host of industries including
nutritional supplements, cosmetics, or agrochemicals (basically
any situation in which biology is exposed to chemistry).
1,2
Metabolic liability can lead to a number of diverse issues, for
example drug−drug interactions (DDIs),
3 including enzyme inhi-
bition, induction, and mechanism-based inactivation,
4 resulting
in substantial variations (one or more orders of magnitude)
of drug concentrations present at target and antitarget sites.
5
These effects potentially lead to a loss of pharmacological
efficacy due to enhanced clearance or toxic effects caused by
accumulation. DDIs may also increase the rate of reactive,
toxic intermediates formed.
6,7 The more the metabolism of a
drug is specific to one enzyme, the more likely is the
occurrence of DDIs.
DDIs caused by monoamine oxidase (MAO) inhibition often
limit the coadministration of multiple drugs. This is problem-
atic in the case of depression and infections, where coadmini-
stration of drugs is common.
8 Because of potentially lethal
dietary and drug interactions, monoamine oxidase inhibitors
have historically been reserved as a last line of treatment, used
only when other classes of antidepressant drugs such as
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sants have failed. Tyramine metabolism can be compromised by
dosing of MAO inhibitors, and in the case of dietary intake of
large amounts of tyramine (e.g., aged cheese
9), one theory is
that tyramine displaces norepinephrine from the storage vesicles
and may result in a cascade in which excess norepinephrine is
released giving a hypertensive crisis. Many drugs are potentially
lethal if ingested with MAO inhibitors. For example tryptamines,
coadministered with an MAO inhibitor, can reach very high
concentrations and result in serotonin syndrome.
10 The
coadministration of drugs which are metabolized by MAOs
requires great care as they may in combination saturate the
capacity of MAO for metabolism, resulting in altered
pharmacokinetics of the drugs and very high concentrations can
be reached on multiple dosing. Another example is change of
behavior, where transient behavioral sensitization to nicotine
becomes long-lasting with addition of MAO inhibitors.
11
Metabolic reactions may also be systematically exploited in
drug design to optimize ADME and toxicity properties
following a prodrug concept.
12 It may remain unclear whether
the parent molecule is responsible for the entirety of the
pharmacological effects observed or if one or several of its
metabolites are contributing to the desired therapeutic effect.
Another aspect to consider is that for a metabolism-activated
prodrug, inhibition of the enzyme required for its activation
may cause a loss of pharmacological efficacy or induce toxicity.
Identification of sites of metabolism (SOMs) on molecules
and the structure of their metabolites can be decisive for the
design of molecules with favorable metabolic properties.
Medicinal chemistry driven ADME optimization programs
can thus systematically address vulnerabilities in proposed drug
molecules (Figure 1).
However, experimental techniques to detect and quantify
DDIs, as well as to determine SOMs and structures of
metabolites are still highly resource-demanding and challeng-
ing,
13 which is why in recent years substantial efforts have been
applied to develop computational approaches to predict these
metabolic outcomes.
In this review, we begin with a general perspective of the
scope of ligand-based and structure-based methods for the
prediction of xenobiotic metabolism. We then provide an
overview of recent developments in computational methods for
predicting (i) SOMs, (ii) structures of potential metabolites,
and (iii) interactions of small molecules with metabolizing
enzymes and metabolic pathways, focusing on CYPs. This
section also includes a comprehensive overview on structure
and MD (molecular dynamics) simulations of this enzyme
superfamily.
We conclude with a perspective and outlook on the scope
and limitations of in silico methods for the prediction of
xenobiotic metabolism.
Overviews of computational methods discussed in this work
are provided in Table 1 and Figure 2.
■ LIGAND-BASED AND STRUCTURE-BASED
METHODS FOR PREDICTING XENOBIOTIC
METABOLISM
Computational techniques for predicting xenobiotic metabo-
lism can be classified into ligand-based and structure-based
approaches. In the first approach, structures of known active
and inactive compounds may be modeled to derive structure−
activity relationships (SARs, where “activity” refers to a measure
of metabolism) and other properties such as SOMs, etc. In the
second approach, efforts are focused on the properties of the
metabolizing enzyme itself, its interactions with the ligand, and
the mechanism of the reaction.
Ligand-based methods need to deal with significant
uncertainties about the binding site environment of a
metabolizing enzyme, in comparison to structure-based
approaches, because the properties of the proximate target
environment a ligand binds to may remain largely speculative if
no structural data are available. Minor modifications of the
ligand may lead to clashes with the protein and, hence, to a loss
of bioactivity. However, for ADME processes, small changes in
ligand structure do not typically result in major changes in
metabolism, presumably due to the flexibility of the
metabolizing enzyme active sites.
There is increasing interest in methods considering the
molecular shape of both ligands and enzyme active sites. While
pharmacophoric interaction patterns have long been established
as a major factor for bioactivity, in recent years, methods for the
inclusion of molecular shape as a key component for molecular
recognition have gained popularity. Besides metabolism
prediction, shape-based methods are also applied in many
areas of computational drug discovery such as protein active
site comparisons, virtual screening, and lead optimization.
Of course, the relative utility of ligand-based and structure-
based computational approaches is not as imbalanced as it may
seem in the first instance. The substantially higher level of
complexity introduced by the consideration of macromolecular
structures raises demands in computational power, expert
knowledge, and manual interaction, as well as reliance on the
phenomenological descriptions of the protein, the ligand, and
their environments.
Figure 1. Xenobiotic metabolism and its broad spectrum of
pharmacodynamic and pharmacokinetic effects. Potential issues of
metabolic liability and biological activity of xenobiotics on
metabolizing enzymes include DDIs (in particular, enzyme induction
and inhibition), which in turn may cause therapeutic failure, toxicity,
and adverse effects. Metabolic reactions can also be exploited for the
rational design of prodrugs.
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dx.doi.org/10.1021/ci200542m | J. Chem. Inf. Model. 2012, 52, 617−648 618Table 1. Overview of Methods for Predicting SOMs, Structures of Metabolites, and Interactions with Metabolizing Enzymes
Methods for predicting SOMs Category Description
Refs
(Examples)
QMBO Reactivity-
based
method
Derives likelihood of a metabolic reaction at a certain atom position from its hydrogen abstraction
energy based on bond order, employing a DFT wave function. Considers accessibility of
hydrogen atoms.
16
CypScore Reactivity-
based
method
Uses AM1-based atom reactivity descriptors to estimate metabolic reactivity of a certain atom
position. Six models to describe various generic CYP metabolic reactions.
17
Metaprint2D Fingerprint-
based data
mining
method
Derives likelihood of metabolic transformations for atoms with a defined atom environment from
data mining of large biotransformation databases. Encodes atom environments using SYBYL
266
atom types in combination with circular fingerprints.
21−24
ADMET Predictor − Metabolite
Module
Machine
learning
method
Derives the likelihood of metabolic reactions to happen at specific atom positions using ANN
ensembles. Classification models allow identification of substrates for five CYP isoforms.
28
ROCS Shaped-focused
method
Uses shape-focused alignment of molecules to known CYP substrates in order to derive a potential
geometric orientation to the catalytic heme iron. Atom positions in the proximity of the heme
iron are considered potential SOMs.
37
Classic docking tools
(AutoDock, FlexX, GLIDE,
GOLD, etc.)
Protein−ligand
docking-
based
method
Evaluate orientation of the ligand to the enzyme catalytic center in order to identify potential
SOMs. Atom positions in the proximity of the heme iron are considered potential SOMs.
51, 52
MetaSite Combined
approach
Uses protein structural information, GRID-derived MIFs of protein and ligand, as well as
molecular orbital calculations to estimate the likelihood of a metabolic reaction at a certain atom
position.
40, 54, 55
Combined pharmacophore,
homology modeling and
quantum chemical approach
Combined
approach
Combines a pharmacophore-based approach, homology modeling and molecular orbital
calculations to pinpoint potential SOMs.
60
SMARTCyp Combined
approach
Utilizes a set of precalculated DFT activation energies in combination with topological
accessibility descriptors for prognosis of potential SOMs (CYP3A4 and 2D6).
61, 62
StarDrop Combined
approach
Combines quantum chemical analysis and a ligand-based model of CYP substrates to highlight
potential SOMs. Takes into account calculated logP values.
64
RS-Predictor Combined
approach
Utilizes a set of 148 topological and 392 quantum chemical atom-specific descriptors in
combination with a SVM-like ranking and a multiple instance learning method to identify
potential SOMs.
15
Machine learning-based
multidescriptor approach
Combined
approach
Takes into account quantum chemical, SASA and pharmacophoric descriptors using a random
forest/ensemble decision tree approach to identify potential SOMs.
65
Machine learning-based
multidescriptor approach
Combined
approach
Employs electrostatic, inductive, energetic, topological, steric, and distance properties in
combination with a SVM to predict potential SOMs of endogenous substrates.
67
Combined quantum chemical/
docking/MD approach
Combined
approach
Combination of quantum chemical methods with docking to account for reactivity, followed by
MD simulations to predict potential SOMs.
69
MLite Combined
approach
Combines quantum chemistry-derived reactivity estimation with docking. 73
Ensemble-based/MD-supported
docking
Protein−ligand
docking-
based
method
Accounts for protein target flexibility with conformational ensembles of proteins generated using
MD simulations and related techniques.
79−82
IDSite Combined
approach
Combination of an induced fit docking approach (GLIDE, PLOP) with a reactivity model
(Jaguar).
84
Methods for predicting
xenobiotic metabolites Category Description
References
(Examples)
MetabolExpert Expert system Uses knowledge database of rules to predict the structures of likely metabolites. Predicts pathways
in animals, plants, or through photodegradation.
88
META Expert system Uses a large dictionary of biotransformations to predict the structure of likely metabolites. Analyzes
metabolite stability. Predicts pathways in mammals, through aerobic and anaerobic
biodegradation.
89
Meteor Expert system Employs a collection of knowledge-based biotransformation rules defined using a dedicated
structure representation language to derive the structure of likely metabolites. Considers
calculated logP values for predictions.
90
University of Minnesota
Pathway Prediction System
(UM-PPS)
Expert system Utilizes biotransformation rules to predict the structure of likely metabolites. Specific to microbial
catabolic metabolism.
91
SyGMa Expert system Predicts structures of likely metabolites based on rules derived from the Accelrys Metabolite
Database and assigns probability scores for each metabolite.
92
TIMES Expert system Employs a biotransformation library and a heuristic algorithm to generate metabolic maps. 93
JChem Metabolizer module Expert system Enumerates all possible metabolites of a given compound. Supports species-specific predictions of
likely metabolites.
94
Metaprint2D-React Fingerprint-based
data mining
approach
Predicts structures of likely metabolites based on the MetaPrint2D data mining approach. 21
Machine learning-based
multidescriptor approach
Combined
approach
See description of this software in Methods of Predicting SOMs. 67
MetaSite Combined
approach
See description of this software in Methods of Predicting SOMs. 40, 54, 55
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Methods for predicting CYP binding
affinity/inhibition by xenobiotics Category Description
References
(Examples)
Linear interaction energy (LIE) MD simulation semi-empirical method for calculating free energy of binding for a ligand using
ensemble averaged nonbonded interaction energies.
156−159
Free energy perturbation (FEP)/
thermodynamic integration (TI)
MD simulation Simulations of unphysical states along a thermodynamic cycle connecting the
bound and unbound ligand form for calculating the free energy of binding.
131, 161
−163
Decision tree, k-nearest neighbor, ANN,
random forest, SVM, etc.
QSAR and machine
learning method:
Classification model
Classify compounds for enzyme inhibition. Allow conclusions to be drawn on
isoform specificity.
202−206,
209
isoCyp QSAR and machine
learning method:
Classification model
Classifies compounds for CYP3A4, 2D6, and 2C9 inhibition. 207, 208
PCA, PLS, multiple linear regression,
etc.
QSAR and machine
learning method:
Regression model
Predict enzyme inhibition rates. 210, 212
−216
CoMFA, GRID/GOLPE 3D-QSAR method:
Classification model
Classify compounds for enzyme inhibition. Allow conclusions to be drawn on
isoform specificity.
222, 224
CoMFA, GRID/GOLPE 3D-QSAR method:
Regression model
Predict enzyme inhibition rates. Allow derivation of 3D properties crucial for
bioactivity.
224−229,
231, 232
Pharmacophore models Pharmacophore-based
method
Predict quantitative and qualitative enzyme inhibition. Allow conclusions to be
drawn on isoform specificity.
213, 233,
236, 238
−240
Protein−ligand docking Protein−ligand docking-
based method
Predict binding mode and binding affinity. Allow conclusions to be drawn on
isoform specificity.
159, 241,
242
Combined pharmacohore ensemble/
SVM approach
Combined approach Uses an ensemble of pharmacophores to account for protein flexibility. 243
Proteochemometric analysis supported
by GRIND and further
physicochemical descriptors
Combined approach Considers protein sequences of 14 CYPs as well as GRIND and further
descriptors for substrates.
244
Combined machine learning, protein
modeling, and docking approach
Combined approach Uses simulated annealing to render the conformational space of the target protein
and docking scores as attributes for subsequent ANN model generation.
246
VirtualToxLab Combined approach Uses flexible docking in combination with a multidimensional QSAR approach
to predict ligand interaction with 16 antitargets, including CYP450 1A2,
2A13, 2C9, 2D6, and 3A4.
247
Methods for predicting CYP
induction by xenobiotics Category Description Examples (References)
PLS using VolSurf
descriptors
QSAR approach Uses atPLS and VolSurf descriptors for the development of a QSAR model for
PXR/AhR interaction.
PXR: 251; AhR: 251
SVM, k-nearest neighbor,
probabilistic neural
network
Machine learning
approach
Uses various machine learning methods to predict human PXR interaction. PXR: 252
Pharmacophore modeling Pharmacophore-
based method
Uses pharmacophores to predict PXR/CAR interaction. PXR: 253−256; CAR:
262
Protein−ligand docking Protein−ligand
docking-based
method
Uses protein−ligand docking to predict PXR/AhR/CAR activation, rationalize
SARs and gain insight on likely molecular interaction modes.
PXR: 256−258, 263;
AhR: 259, 263; CAR:
263
GRID/GOLPE 3D-QSAR method Uses MIF-derived 3D-QSAR models to predict CAR interaction. CAR: 262
VirtualToxLab Combined approach Uses flexible docking in combination with a multidimensional QSAR approach to
predict ligand interaction with AhR and 15 other targets (see above).
AhR: 247
Figure 2. Overview on topics and computational approaches covered in this review.
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patterns from static structures of protein−ligand complexes
without considering time-dependent conformational fluctua-
tions, unless combined with even more resource-intensive MD
simulations or similar methodologies (see the section on
Molecular Dynamics Simulations on the Structure of CYPs).
Receptor−ligand conformations observed in X-ray crystallo-
graphic experiments may include crystal packing effects and
other experimental uncertainties.
14 Also, an observed ligand
pose may not necessarily reflect the relevant binding mode for
the metabolic transformation.
Structure-based methods that predict receptor−ligand bind-
ing geometry (e.g., for SOM prediction) should ideally take
some of the changing properties upon complexation of both the
ligand, the protein, and the ligand−protein complex into
consideration. For example, desolvation and entropic compo-
nents often play a dominant role in the energetics and
geometry of ligand binding; however, both desolvation and
entropic effects are difficult to model accurately (including
diffusion, on−off rates and solvent reorganization). The
approximations necessary to enable predictions to be made in
a reasonable time-scale are significant. Additionally, ligands
typically approach a binding/active site through a size-limiting
access channel, and it is nontrivial for structure-based
approaches to simulate the dynamic changes in geometry
required for the approach of the ligand to the binding site.
Ligands that are metabolized, however, may be assumed to
include all these properties, which to some degree are
intrinsically included in ligand-based models.
Despite the challenges, structure-based methods have signifi-
cantly contributed to the rationalization of metabolic reactions and
with rapidly advancing technologies for structure elucidation and
computation of dynamics and reactivity structure-based methods
are becoming ever more predictive and accurate. Certainly, the
combination of both ligand-based and structure-based approaches
is most promising, leading to synergistic effects between different
algorithmic approaches that allow more comprehensive descrip-
tions of metabolic reactions.
■ PREDICTING SITES OF METABOLISM
Identifying SOMs of a molecule may give decisive hints in the
development of a medicinal chemistry strategy to optimize
metabolic properties and, consequently, crucial parameters such
as toxicity, bioavailability, and bioactivity. Chemical reactivity
and orientation of the ligand bound to the catalytic site of the
enzyme are key for the location of SOMs.
Today, a plethora of computational approaches are available,
which attempt to identify the most likely SOMs. Algorithms
include reactivity-based approaches, fingerprint-based data
mining approaches, shape-focused techniques, molecular
interaction fields (MIFs), protein−ligand docking, and
combinations of methods (Figure 2). Most of the techniques
available to date consider a single aspect of metabolic reactions,
such as the reaction energy barrier, geometrical properties, or
pharmacokinetic properties for predicting SOMs or potential
metabolites.
13 In reality, however, a combination of factors
(energetics, geometry, reaction mechanism, etc.) is decisive for
a metabolic reaction to take place and hence combined
approaches render a more realistic and more accurate view of
biotransformations.
To quantify the SOM prediction performance of an algorithm,
it is usually tested on a set of compounds for which at least one
SOM has already been identified experimentally. Many testing
protocols use the “Top-N” metric, which for a given compound
is the occurrence of an experimentally confirmed SOM within
the N top-ranked predicted SOMs. A major insufficiency of this
metric is that it does not account for the fact that for some
substrates the prediction of a SOM may be biased. This metric
is for example strongly influenced by the size of a molecule, as
larger molecules intrinsically have more putative SOMs. More
recently, the “Lift” metric has been introduced in order to
overcome this bias.
15 This measure includes the prediction
accuracy of a computed model compared to a random model.
Reactivity-Based Approaches. Reactivity-based ap-
proaches utilize descriptors that are derived from the electronic
structure of the molecule to predict its liability for metabolic
transformations (see “Reactivity of CYPs” for more information
on the reaction mechanism of CYPs). For computational
efficiency, semi-empirical quantum mechanical methods can be
used. As a preamble to the main calculation, a 2D representa-
tion of a ligand must be converted to a 3D representation and
the correct hydrogen addition performed considering tauto-
meric states and pKa values of ionizable groups, followed by
geometry optimization.
QMBO
16 estimates hydrogen abstraction energies based on
bond order. Starting with the premise that the hydrogen
abstraction by Compound I (see “Reactivity of CYPs”) from a
substrate is the rate-limiting step, the method relates the
reactivity of each hydrogen atom to the strength of its covalent
bond. Using a wave function generated from density functional
theory (DFT), bond orders for all C−H bonds in a substrate
are calculated, and then normalized. Bond strength is correlated
to deviations from average bond orders. Corrections are made
for buried hydrogen atoms through scaling by a factor that is a
function of the solvent accessible surface area (SASA) of the
hydrogen atom.
Given that the highly electrophilic Compound I has received
an electron from the substrate, the substrate will form a
positively charged radical intermediate, and where this spin hole
is localized, there will be a likely SOM. Using a DFT wave
function, the QMSpin
16 tool calculates spin densities on all
hydrogen atoms using Fermi contact values. The same SASA
scaling approach used in QMBO is applied. Of these two
methods, QMBO is reported to perform slightly better than
QMSpin. Using the Top-3 metric for SOMs over 81 molecules,
QMBO predicts 84% and QMSpin 78%.
16
CypScore
17 makes use of a range of atomic reactivity
descriptors generated from an AM1
18 wave function, with
molecular properties derived from this using the software
VAMP
19 and ParaSurf.
20 These descriptors are used for the
generation of individual models for the most important
reactions catalyzed by CYPs. Using the Top-3 metric, 87% of
SOMs were identified from a test set of 39 molecules.
Most reactivity-based approaches put substantial weight on
correction factors often related to topological properties
describing accessibility. These are discussed in the section
“Combined Approaches” below.
Fingerprint-Based Data Mining Approaches. Finger-
print-based data mining approaches describe the presence or
absence of chemical features within a molecule and relate these
to metabolic reaction sites and products. The chemical
environment of a SOM is associated with a fingerprint
descriptor enabling predictions to be made about novel
compounds by searching for locations with the same or similar
fingerprint within the target molecule. The relative likelihood of
a fingerprint being associated with a SOM can be calculated
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method can be trained on a data set of known metabolic
transformations. This can suggest a ranking for different sites
within a molecule according to their likelihood of being a SOM.
Metaprint2D
21−24 is a data-mining tool that identifies SOMs
on the basis of circular fingerprints. The software package is Java-
based, and an online service
25 allowing prediction of SOMs for
uploaded or drawn structures is available. Metaprint2D mines
large biotransformation databases such as the Accelrys
Metabolite Database,
26 which contains more than 100,000
metabolic transformations. For each atom of each substrate−
metabolite pair included in the database, the atom type at the
SOM, as well as its proximate environment, is encoded in a
fingerprint. In order to derive probabilities for a specific atom
to be involved in a metabolic interaction, the occurrence of
each of the encoded atom environments is calculated and
compared to the number of biotransformations recorded in the
database for this particular atom environment. The normalized
occurrence ratio does not reflect the absolute probability of a
metabolic reaction to occur, but can indicate the prevalence of a
reported transformation in the literature. The Metaprint2D
algorithm uses a memory cache to store the fingerprints, allowing
results to be returned in under a second. A disadvantage of this
data mining approach is that predictions cannot be made about
novel atomic sites where the fingerprint does not exist in the
data set. MetaPrint2D detects novel sites within a query mole-
cule and acknowledges that they are outside the applicability
domain when it presents the metabolic predictions in its
graphical results output.
Tests of the method using compounds added to later
versions of the Accelrys Metabolite Database (other than that
used for model training) indicate that SOMs are correctly
predicted in about 70−80% of cases among the three highest-
scored atom positions.
21
Metaprint2D-React
21 is an extension of MetaPrint2D that
allows prediction of metabolic products on the basis of the
structure of a substrate (see “Predicting Xenobiotic Metabo-
lites”). The metabolites proposed by MetaPrint2D-React are
ranked according to the relative occurrence of matching
transformations in the training database associated with that
fingerprint pattern. A freely accessible online version of the
software is available.
27
Machine-Learning Approaches. SOM prediction meth-
ods based on machine learning methods such as support vector
machines (SVMs) and artificial neural networks (ANNs) have
recently gained more attention for use in SOM prediction.
Simulations Plus have introduced the Metabolite Prediction
module
28 to their ADMET Predictor software. Like Meta-
Print2D, this prediction tool is trained on the Accelrys
Metabolite Database. This data set has been curated and
some further sources for metabolic reactions were added.
Models for the prediction of SOMs are based on artificial
neural network ensembles (ANNEs) derived using atomic
descriptors to generate an artificial neural network classification
(ANNC) model. For each atom of a molecule, a score (0−1)
for the likelihood of a metabolic reaction to happen is assigned.
In addition to that, a substrate classification model can predict
whether a compound is a substrate of five CYP isoforms.
Further examples include combining different methods,
which are discussed in the section “Combined Approaches”.
Shape-Focused Approaches. The concept of shape-
focused methods is based on the observation that compounds
sharing a similar shape have a high probability of binding to the
same receptor. The shape of a ligand is thought to resemble the
partial complementary shape of the binding site. In this way,
shape-focused methods attempt to identify bioactive molecules
by molecular shape recognition. Shape similarity between the
bioactive template molecule superimposed upon a candidate
molecule is used for a quantitative calculation of the likelihood
for metabolism, with the site identified from the proximity to
the experimentally determined site on the template molecule.
Shape-based methods can be effective and have become increas-
ingly popular in the area of similarity-based virtual screen-
ing
29−34 and bioactivity profiling.
35 Shape-focused methods are
advanced versions of shape-based methods, where alignment
and ranking are performed using a chemistry-aware algorithm.
The inclusion of chemical information (resembling pharmaco-
phoric constraints) to molecular shape can be an additional
factor in improving the accuracy of these methods.
30
The shape-focused screening method Rapid Overlay of
Chemical Structures (ROCS)
36 was employed to predict the
SOM of CYP2C9 substrates.
37 Flurbiprofen, a substrate of
CYP2C9 that is hydroxylated by the enzyme at position 4′, was
extracted in a protein-bound conformation from an X-ray
structure for use as a structural template for a ROCS search.
The assumption was that the SOM of any CYP2C9 substrate
should be located in proximity to the SOM of flurbiprofen.
ROCS was employed to superimpose 70 known CYP2C9
substrates to the flurbiprofen template and encouraging results
were found: The SOMs of 60% of all investigated molecules
were positioned within 3 Å of the 4′-hydroxylation site of
flurbiprofen, with 39 (89%) out of the 44 top-ranked molecules
correctly predicted. Additionally, alignments were further
analyzed including the protein background to evaluate whether
the positioning of the SOM also relates to the heme iron. The
average distance between the known SOM and the heme iron
was found to be 5.21 ± 0.95 Å, which is in agreement with
experimentally observed substrate−heme distances. The
approach is rapid, largely unbiased and does not require
manual interaction, which allows large-scale profiling of drugs
and other similar molecules to a defined substrate.
Molecular Interaction Fields. Molecular interaction fields
(MIFs) are one of the most established and most versatile
concepts in drug discovery. The idea of MIFs is to encode the
variation of interaction energies between a target molecule and
a chemical probe in 3D space. The probes are usually an atom,
a point charge, or a molecular fragment and depending on the
physicochemical properties of the probe, distinct characteristics
about the target molecule can be derived from the calculated
interaction energies.
In ligand-based design, MIFs may be used to derive 3D-QSAR
models and pharmacophoric representations and to predict
pharmacokinetic parameters such as cell permeability and
metabolism. In structure-based research they are employed to
analyze structural features of macromolecules such as protein−
ligand and protein−protein interactions. MIFs have been
reported to be useful to elucidate information for rational
drug design on how to optimize protein−ligand interactions,
areas of ligands vulnerable to metabolism, and ligand/isoform
specificity. There are currently a number of implementations of
MIFs in CYP-related metabolism of xenobiotics and examples
covering many of these aspects have been published (as
discussed in the following and in “Predicting Interaction of
Xenobiotics with CYPs”).
GRID
38 has been developed as a tool to explore and
characterize protein structures for areas favorable for
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known for its key role in the design of the anti-influenza drug
zanamivir.
39 Common probes in GRID include DRY
(representing hydrophobic interactions), N1 (representing
hydrogen bond donors, derived from planar NH such as
amides) and O (representing hydrogen bond acceptors derived
from a sp2 carbonyl oxygen).
An example of a MIF-based software package for predicting
SOMs is MetaSite.
40 Further approaches utilizing MIFs have
been reported, in general combined with other computational
techniques. For more detail on these approaches the reader is
referred to “Combined Approaches”.
Protein−Ligand Docking. Protein−ligand docking has
become an integral part of today’s rational lead identification
and optimization process. By 2004, it is estimated that about 50
new entities had reached clinical trials and/or market approval
guided by structure-based drug design.
41 With crystal structures
available for the major human CYP isoforms, protein−ligand
docking is showing promise for the analysis and prediction of
CYP-induced metabolism.
7
Docking consists of two parts. First, the ligand is docked into
the receptor binding site. This is the actual docking process and
involves sampling the conformational space of the ligand within
the binding site. In the second step, the generated docking
poses are evaluated and some measure of affinity or the fit of
the ligand for the receptor is estimated. This step is also
referred to as scoring.
By using protein structures directly as model systems, docking is
largely unbiased by known SAR, offering opportunities to reveal
entirely new binding modes. Current ligand docking methods
are limited by many approximations including approximate
descriptions of desolvation, entropic and enthalpic compo-
nents, as well as dynamic structural changes of the protein upon
ligand binding. Generally, the faster the method, the more
significant are the approximations made. Packing forces in the
protein template may also introduce bias to the model. Ligand-
induced mobility of the binding site becomes apparent when
comparing redocking with cross-docking results. In the first
case, a docking algorithm is used to redock a ligand extracted
from the binding pocket (no induced fit), while in the latter
case, ligands are cross-docked to target structures derived from
protein structures templated to an alternative ligand. Cross-
docking in general shows significantly lower accuracy compared
to redocking. The reasons for this include the conformational
changes induced in both the protein and ligand.
42
Docking may allow the derivation of SOMs by relating the
proximity of ligand atoms of a docking pose to the catalytic
center of the enzyme. Additionally, docking also allows investi-
gation of binding properties of ligands to their target proteins
and suggests SAR (see “Predicting Interaction of Xenobiotics
with CYPs”). Direct consideration of the protein environment
allows the elucidation of residues involved in ligand binding
and can allow rationalization of different metabolic properties
of enantiomers by analysis of the protein−ligand interactions.
This information is valuable for the design and optimization of
drug candidates.
Generally speaking, current docking algorithms offer adequate
performance for elucidating the ligand-binding mode provided
an appropriately complementary (to the ligand-binding pose)
protein structure is applied that covers the relevant receptor
conformation. Cross-docking still poses significant problems.
Despite decades of research, some cardinal issues of docking
and in particular of scoringhave not yet been resolved.
7
Key aspects such as diffusion, entropy, and solvation effects
remain largely neglected by scoring functions.
43
A systematic investigation of the impact of water molecules
present/absent in the active site of 19 CYP structures
44 has
been reported for AutoDock,
45 FlexX,
46 and Genetic Optimi-
zation for Ligand Docking (GOLD).
47 Performance was
compared for the process of docking into water-free binding
sites, binding sites with crystallographic water present, and
binding sites with water molecules placed using GRID. It was
found that the consideration of crystallographic water
molecules generally improves the docking accuracy of all
three approaches and that the introduction of water molecules
predicted with GRID leads to a further increase of accuracy
with regard to root-mean-square deviations (RMSD) of the
docked ligand from the experimentally determined position and
SOM prediction accuracy.
In a follow-up study focusing on CYP2D6, considering
several different scenarios for the inclusion of water, it was
confirmed that the placement of water molecules almost always
leads to an increase in docking accuracy.
48 Correctly placed
water molecules improve docking-based SOM prediction (as
well as virtual screening accuracy). The combination of GOLD
with ChemScore
49 was found to perform particularly well.
Recently, Santos et al.
50 systematically investigated the impact of
water molecules on protein−ligand docking of substrates of
CYP2D6. Representative protein conformations used for
docking were generated using MD simulations of an X-ray
structure of (R)-3,4-methylenedioxy-N-ethylamphetamine (MDEA)
bound to CYP2D6. Hydration sites were derived from the
trajectory, and water molecules were placed at the computed
positions for water in the protein frames used for docking.
Eleven substrates similar to MDEA and 53 structurally distinct
compounds were then docked into the representative protein
conformations. These results indicated that water molecules
placed into the binding site might have a beneficial impact on
the docking performance of substrates closely related to the
crystallographically determined ligand. However, this effect is
strongly dependent on the protein and ligand conformation.
Also, there seemed to be no benefit from the inclusion of MD-
derived water molecules for substrates dissimilar to MDEA.
Overall, in this case, water molecules were found rather weakly
bound inside the CYP2D6 binding pocket, with an average
residence time below 10 ps, which may contribute to the lack of
beneficial effect on inclusion of specific water on docking and
the observed substrate promiscuity of the enzyme.
Examples of the successful prediction of SOMs include a
study by Vasanthanathan et al.,
51 who performed docking
experiments on CYP1A2 employing GOLD with various
docking scenarios. These scenarios differed in the treatment
of the crystallographic water molecules mediating a hydrogen
bond between the enzyme and the ligand and in the scoring
function used (ChemScore or GOLDScore). Docking was
deemed successful if the known SOM of a docking pose was
computed to be within a 6 Å radius from the heme iron. While
docking performed adequately to allow the elucidation of
binding orientations and conformations of ligands as well as
moderate enrichment rates during virtual screening, superior
performance in classifying individual compounds into those
that were or were not metabolized was observed for machine
learning methods (reviewed later). In contrast to several other
docking studies on CYPs, the authors did not detect a
significant benefit from including water molecules in protein−
ligand docking (see below).
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52 used Grid-based LIgand Docking with
Energetics (GLIDE)
53 and a homology model for CYP2D6 to
predict the SOMs of 16 substrates. Predictions were deemed
correct if the known SOM is located less than 4.5 Å from the
catalytic iron among the five top-ranked docking poses, which
was the case for 85% of all investigated cases. Docking results
obtained from this CYP2C5-derived homology model were
significantly better correlated to the experiment than docking
results obtained from a X-ray structure of apo CYP2D6.
Scoring ligand interactions with the heme prosthetic group is
challenging, requiring specific parametrized scoring functions.
Extensive hydrophobic surface areas that are present in CYPs
contribute to the difficulty of docking ligands to this protein
family. The lack of strong, directed hydrogen bonding
interactions makes scoring functions highly dependent on the
interpretation of weak van der Waals interactions between the
ligand and the enzyme surface.
With today’s computer hardware, computational resources
are hardly an issue for most docking methods. A significant cost
factor of docking is the degree of expert knowledge on the
target under investigation and the interpretation of results from
the docking algorithm itself, not only during setup but also during
final data analysis. Relatively sparse coverage of structural
information on CYPs (they are conformationally labile) limits
the applicability of docking for this enzyme family. Techniques
to extend the scope of docking include homology modeling and
MD simulations, as discussed in the following section.
Combined Approaches. As pointed out above, chemical
reactivity and accessibility are the decisive aspects for a
metabolic reaction to take place. It would not be anticipated
that a metabolic reaction would proceed at a highly reactive site
of a molecule that, for steric reasons, cannot be oriented within
the CYP to interact with the reaction center. In such a case, a
method purely considering reactivity-related aspects is likely to
fail. Consideration of both aspects is crucial, which is reflected
in the variety of combined approaches that have been
reported.
13
MetaSite is an integrated software package for predicting
CYP-mediated metabolism.
40 It evolved from earlier ap-
proaches combining GRID and ALMOND
54,55 and includes
several different components to predict SOMs: MIF-based
modules for the analysis of protein and ligand characteristics
and quantum-chemical and knowledge-based components to
account for metabolic reactivity. The software package encodes
the characteristics of CYP enzymes in the form of a fingerprint
that is independent of the initial conformation of side chains in
order to account for protein adaption induced by ligand
binding. Atoms of the small organic molecule under
investigation are categorized by their GRID probe counterparts
to reflect their hydrogen-bonding and charge capabilities as well
as their hydrophobic characteristics. Subsequently, they are
transformed into a distance-binned representation, resulting in
a fingerprint for each GRID probe category. The descriptors of
the CYP structure and of the ligand are then compared in order
to quantify the exposure toward the catalytic heme moiety for
any of the ligand atoms, which relates to the liability for
metabolism. MetaSite includes a reactivity component that
estimates the likelihood of a metabolic reaction on the basis of
molecular orbital calculations, estimating the energetic barrier
of hydrogen bond abstraction. The overall susceptibility at a
certain atom position is then derived from a probability
function accounting for both accessibility and reactivity. Only
atoms obtaining high values for both measures are considered
likely to be involved in metabolic reactions. The software also
includes a knowledge-based reaction mechanism component
for weighting preferences for types of metabolic reactions for
the individual CYP isoforms.
56
Results of a MetaSite analysis are reported as a histogram bar
chart indicating the likelihood of metabolism for any of the
ligand atoms. An interesting feature of MetaSite is the Partial
Contribution plot, which indicates moieties of the compound
that are expected to interact favorably with the CYP isoform
under investigation. This can provide valuable hints on how to
optimize the metabolic properties of a ligand.
57
A structure-based approach such as this is limited to enzymes
where a protein structure or homology model is available.
A drawback of MetaSite is that it reports only the relative
likelihood for a specific metabolic reaction to occur at a certain
atom position. Results among different molecules cannot be
directly compared. This is also the case for the Partial Con-
tribution plot.
The authors of MetaSite claim a success rate of 85% for
tagging a known SOM among the top-2 ranked atom positions.
It was successfully employed to identify the main metabolites of
the angiotensin receptor antagonists lorsartan, candesartan,
valsartan, and tasosartan.
54 In a study by Zhou et al.,
58 MetaSite
was found to correctly predict the SOM among the three
highest-ranked atom positions for 78% of the investigated
compounds. A more recent study employed MetaSite for the
identification of SOMs to support experimental mass-
spectrometric metabolite identification.
59 The SOM top-ranked
by MetaSite were experimentally confirmed for 55% of the
analyzed compounds. The hit rate improved to 84% when
considering the three top-ranked atom positions.
De Groot et al.
60 reported one of the earliest approaches
combining several methods to pinpoint SOM. They employed
ligand-based pharmacophores, homology modeling, and
molecular orbital calculations (AM1
18) to identify the SOM
of substrates of CYP2D6. On the basis of the information
gained from the three domains, the SOM of six out of eight
investigated ligands could be correctly identified.
Rydberg et al. have released an open-source, Java-based,
SOM predictor called SMARTCyp.
61−63 This software package
contains a database of precalculated DFT activation energies for
various ligand fragments undergoing a CYP3A4-mediated
transformation. SMARTCyp performs a lookup for a ligand
using this database that contains SMiles ARbitrary Target
Specification (SMARTS)-based fragments that are matched, in
conjunction with an accessibility descriptor to provide a ranking
of the SOM. Using the Top-2 metric, 76% of SOM are
identified over a test set of 394 compounds. The tool is fast
because of the precached QM results. Most recently,
SMARTCyp was extended to predict reactivities for CYP2D6.
63
StarDrop
64 predicts SOM on the basis of quantum chemical
analyses of molecules. For each atom of a molecule, a metabolic
site liability reflecting the potential metabolite formation is
computed. The metabolic site liability of a ligand atom is
denoted by values between 0 and 1. This is derived from an
estimate of the hydrogen abstraction, which is related to the
enzyme decoupling rate. While the same quantum chemical
module is used for all CYP isoforms, specificity is assessed by
alignment of the query molecule to a ligand-based model
derived from known substrates of the respective isoform. Also
logP, which appears to influence CYP-mediated metabolism
(see “Expert Systems”), is taken into account. StarDrop was
reported to give success rates comparable to SMARTCyp.
62
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RegioSelectivity (RS)-predictor
15 is a recently released, isoform-
specific approach to predict SOM. It utilizes 148 topological
and 392 quantum chemical atom-specific descriptors, a support
vector machine (SVM)-based ranking, and a multiple instance
learning method. Some of these descriptors are modified to
include contributions from neighboring atoms. Using the Top-
2 metric, 78% of SOMs were identified, outperforming SMARTCyp
and StarDrop using either the Top-2 or Top-3 metrics. The
authors also supply their 394 compound test set in their
supporting materials. This is annotated with experimental SOMs
in addition to StarDrop and SMARTCyp predicted SOMs. This
is an excellent resource for comparison testing of future methods.
Hasegawa et al.
65 have developed a machine learning-based
approach for the prediction of SOMs related to CYP3A4-based
metobolism. It combines five quantum chemical descriptors
related to reaction energies plus the activation energies calculated
for the SMARTCyp approach to account for reactivity. Their
approach also considers the solvent accessible surface area
(SASA) to estimate the exposure of a ligand atom to the heme
iron and pharmacophoric constraints to reflect the require-
ments of CYP3A4 for ligand binding. The latter were derived
from known substrates using MOE.
66 Random forest/ensemble
decision trees were employed to predict metabolic sites with
these models, with k-nearest neighbor as a baseline method. The
model considering only reactivity-related descriptors and SASA
was outperformed by the models accounting for pharmacophoric
requirements. The best-performing model included all three
types of descriptors, with pharmacophoric constraints limited to
a distance maximum of 10 Å, employing the random forest
algorithm. Known SOMs were correctly predicted in 82% of all
investigated cases among the two top-ranked atom positions. It
should be kept in mind that only 10 molecules were contained in
the test set, which is rather small when judging performance of the
model in real-world situations, where new molecules will almost
certainly be outside of the applicability domain.
A method to predict the metabolic reactivity of small endo-
genous metabolites has recently been presented that combines
expert knowledge, computational chemistry, and machine learn-
ing.
67 On the basis of the Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathway database,
68 4843 reactions were
characterized and classified into 80 different reaction classes.
SMARTS patterns were used to define chemical substructures
(reaction centers and surrounding moieties), and the physico-
chemical properties of these were encoded using electrostatic,
inductive, energetic, topological, steric, and distance properties.
A SVM binary classification model was trained for each reaction
center SMARTS pattern in order to predict whether or not a
certain atom position is a SOM. A score was obtained for
candidate reaction centers of a molecule, which was then used
to rank the likelihood of a metabolic reaction taking place.
A 3-fold cross validation was performed, obtaining an average
sensitivity of 0.74 and an average specificity of 0.87. Com-
parable results were found when applying the method to
predict molecules that have been recently added to the KEGG
database and which were outside of the training set.
Interestingly, the four most important features identified were
distance properties (encoding the geometrical position of a
reaction center in a small organic molecule). The encouraging
results obtained with this approach make it an interesting
opportunity to extend its applicability domain to xenobiotics.
Several studies employed protein−ligand docking in com-
bination with other approaches to predict metabolism. Lacking
a component to account for reactivity, docking is frequently
combined with quantum chemical methods in order to generate
a more accurate description of the highly complex catalytic
process. In this respect, the hydroxylation and O-dealkylation
reactions of sirolimus (rapamycin) and everolimus (RAD-001)
catalyzed by CYP3A4 were analyzed using a combined
quantum chemical/docking/MD simulations approach.
69 The
electronic properties of both CYP3A4 substrates were
described employing B3LYP DFT. The substrates were also
analyzed by docking on a CYP3A4 homology model using
DOCK
70 and subsequent MD simulations using Assisted
Model Building with Energy Refinement (AMBER).
71,72 The
combined approach turned out to be useful to extend
knowledge on electronic and orientation effects of substrates
of CYP3A4.
MLite
73 is a combined model for CYP3A4-mediated
metabolism, employing protein−ligand docking and the
quantum chemical reactivity estimation method developed by
Korzekwa et al.
74 and Jones et al.,
75 see above. Hydrogen atoms
exposed to the heme iron were identified by docking and
reactivity was considered on the basis of the results of quantum
chemical calculations. In the case of O-dealkylation, a penalty
for the activation energy was required to lower the number of
incorrect predictions by the reactivity-based approach. The
optimized model gave 76% correct predictions for the 25
compounds of the test set when considering the two highest-
ranked atom positions for each molecule. This approach is
related to a further method developed by this research
consortium,
76 which also employed the semi-empirical
(AM1
60) method developed by Korzekwa et al. and Jones et
al. for reactivity estimation, in this case for CYP1A2. AutoDock
was used to orientate the ligands in the binding site to examine
potential SOM and to estimate binding free energies. The
overall prediction of SOM was derived from both measures.
The SOMs of eight out of twelve substrates were correctly
predicted as the primary SOM and for all of them as the
secondary SOM.
Insufficient structural data on the conformational flexibility of
CYPs is still limiting the applicability of docking approaches for
this enzyme family. Homology modeling is one approach to
address this problem, in order to derive structural models from
closely related target structures that can serve as a template for
model generation. Several CYPs, however, exhibit extraordinary
levels of flexibility, which is a major problem for structure-based
approaches in general. Docking algorithms are highly
susceptible even to marginal conformational changes of the
target structure. The approach benefits greatly from using
collections of target structures crystallized in the presence of
ligands of distinct shape and binding modes, so-called ensemble-
based docking.
77 Apo structures of a target in general perform
less well compared to holo structures due to the absence of a
ligand inducing conformational shifts in the binding site.
52
If the relevant conformational space of a target is not
adequately covered by experimental structures, representative
target conformations from MD simulations may boost docking
performance, in particular in cases where heterogeneous
binders induce conformational shifts in the binding region.
77
Thanks to its remarkable flexibility,
78 CYP3A4 is a prime target
for ensemble-based docking approaches. A recent study
employing an ensemble of CYP3A4 structures derived from
several MD simulations to identify SOMs points out the
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catalytic binding site.
79
Hritz et al.
80 found that the binding site of the apo structure
of CYP2D6 is too tight to facilitate the binding of 80% of 65
investigated substrates of this isoform. By employing an
ensemble-based approach, however, they were able to
successfully identify the correct SOM for all of the ligands
with at least one of the MD-derived target conformations. In
this approach, the known substrates were docked to an
ensemble of 2500 protein conformations of CYP2D6 derived
by MD simulations from structures with five heterogeneous
substrates bound in order to simulate the induced fit effect and
thermal motion of the enzyme. To speed up future docking
runs, a binary decision tree was derived that allows
identification of the best suitable protein conformation for
docking specific ligands. In this way, Hritz et al. were able to
successfully predict the SOM of CYP2D6 substrates for 80% of
all cases when docking to the single protein conformation
selected by the decision tree model.
Instead of generating an ensemble of protein conformations
for subsequent docking, MD simulations can also be employed
for refinement of docking results. For example, Keizers et al.
81
found that automated docking of ligands to CYP2D6 structures
is not accurate enough to reflect the ligand orientations
identified in experiments. Using docked poses as a starting
point for MD simulations, they found a significant improve-
ment in ligand orientation and SOM prediction.
Moors et al.
82 derived an ensemble of 1000 protein
conformations on the basis of a X-ray structure of CYP2D6
employing tCONCOORD
83 (which employs a set of distance
constraints to explore the conformational space). Carbons or
atom groups with one or more hydrogen atoms attached were
considered potential SOMs. The closest distance between these
hydrogen atoms and the heme iron was used to identify the
likely SOMs. The optimum of that distance was determined to
be 2.7 Å. Several different docking and scoring protocols were
explored, obtaining AUC (area under the ROC curve) values of
up to 0.93 for an independent test set.
IDSite
84 is a combined approach based on the Schrödinger
software GLIDE, Protein Local Optimization Program (PLOP,
implemented to the Schrödinger software suite as the Prime
85
package) and a reactivity model derived using Jaguar.
86 First,
the ligand is placed into the CYP active site using docking
(GLIDE). Then, two distinct refinements are carried out using
PLOP. This includes both the refinement of protein side-chains
and the conformation and orientation of the ligand itself. Poses
are filtered considering their structures and energies and
clustering by similarity of the ligand conformations is
performed. In the last phase, the best poses are collected on
the basis of a physical score, which considers the intrinsic
chemical reactivity (based on a reactivity model derived from
DFT calculations employing the B3LYP functional with the
6-31G* basis set) of potential SOM as well as the energy of the
ligand poses. Its application on CYP2D6 has been reported
recently
84 and models for other CYP isoforms are currently
under development. For a test set of 56 CYP2D6 substrates, the
correct SOM could be recovered for 83% of all cases. When
using a training set of 36 compounds to fit four parameters
(rescaling of the PLOP energy with two parameters, fitting
radical intrinsic reactivities and score cutoff), 94% of the known
SOMs of a test set of 20 compounds were successfully identi-
fied. Computational power appears to be limiting the applica-
tion of this approach. The authors report a calculation time of
approximately 450 h on a single 2.2 GHz AMD Opteron 6174
processor for a compound with three rotatable bonds.
■ PREDICTING XENOBIOTIC METABOLITES
The identification of metabolites of small organic molecules
contributes to the understanding of ADME and pharmaco-
logical properties. Experimental identification of metabolites is
highly demanding in infrastructural resources, expert knowl-
edge, and time. If enough material is available, NMR allows
structure elucidation of metabolites. Mass spectrometry (MS) is
particularly valuable for the analysis of small amounts of
material. Most common experiments are liquid chromatog-
raphy/mass spectrometry (LC/MS) or liquid chromatography/
tandem mass spectrometry (LC/MS/MS), which allows the
identification of moieties of a molecule where the biotransfor-
mation has taken place (even if they do not always allow for the
identification of SOMs). These experimental methods can
decisively benefit from computational approaches supporting
data analysis to pinpoint the actual SOM. For extensive reviews
on these experimental approaches the reader is referred to refs
57, 59, 87.
While numerous computational methods aim to predict
SOMs, only a very few approaches have been developed so far
that allow prediction of the products of xenobiotic metabolism.
Prediction methods are dominated by expert systems. Addi-
tionally, a fingerprint-based data mining approach is available
and very recently an SVM-based technique has been reported,
which, however, focuses exclusively on endogenous metabolites
(see below).
Expert Systems. A number of expert systems have been
developed that aim to predict the sites and products of
metabolism using dictionaries of biotransformations. These
approaches are based on knowledge rules, which are typically
developed from a reservoir of in vivo and in vitro experimental
results. They are inherently subjective in their nature as they are
based on “expert” human knowledge rather than “robust and
objective computational estimates”, although given the
approximations involved in most computational methods,
these can of course be poor substitutes for the real experimental
conditions. So, expert systems have a strong history in this area
and they can help bridge the gap between empirical knowledge
and hard data. Potential metabolites are identified by searching
a query molecule for the presence of a target fragment and
converting this into a product fragment, as defined by a
biotransformation dictionary.
The main drawback with this approach is the generation of a
combinatorial explosion of predictions, as all possible
combinations of transformations permitted by the dictionary
are considered. Therefore, a key challenge is to prioritize the
results and to stop when it is deemed that the molecule has
been transformed into a sufficiently water-soluble state to
enable excretion from the body. A further caveat is that most
expert systems tend to contain combined data and rules for
many different mammalian species and so are useful as a
general indicator of biotransformations in the “average”
mammal. However, metabolic pathways can be very different
even in closely related mammalian species, so some expert
systems have been developed to allow filtering of specific
subsets of the data to a specific species.
Examples of expert systems include MetabolExpert,
88 META,
89
Meteor,
90 University of Minnesota Pathway Prediction System
(UM-PPS),
91 Systematic Generation of potential Metabolites
(SyGMa),
92 and TImes MEtabolism Simulator (TIMES),
93 as
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user to amend or add new rules to tailor the program to their
specific needs and typically display the results as a tree of
metabolites depicting multiple pathways and molecular struc-
tures. The main differentiating features apart from different data
sources and knowledge rules include the methodologies used to
prioritize predictions and terminate the chain of predictions.
MetabolExpert was one of the pioneering attempts at a
metabolic site predictor, created in 1985. The knowledge
database contains rules, which include substrate and metabolite
listings but also contain lists of substructures, which inhibit or
promote the reaction. The system lists all potential metabolites
without applying any ranking system and predictions are
terminated once known phase II metabolites are generated.
Features of this system include the presentation of the results in
a dendrogram showing chemical formulas along with hydro-
phobicity values and the generation of first- and second-order
kinetics data. Additional enhancements include modules
specific to animal and plant metabolism and soil degradation.
META uses a larger dictionary of biotransformations, each
assigned with a priority enabling the metabolites to be arranged
hierarchically to manage the combinatorial explosion problem.
A genetic algorithm is used to prioritize the transformations
dictionary. Additionally, this system uses quantum mechanical
descriptors to test a proposed metabolite for stability and
convert to a stable conformation if necessary. Further metabolic
products are only generated after a stable conformation has
been achieved. Subsets of the metabolic dictionary can be
chosen to allow focus on specific areas such as mammalian
metabolism, aerobic and anaerobic biodegradation.
Meteor extends the concept of biotransformation rules by
using a structure representation language to describe atoms and
bonds and is able to include descriptors such as charge and
valency. This enables a more sophisticated description of the
activating biophore rather than just functional groups. Over-
prediction is countered by classifying transformations as
probable, plausible, equivocal, doubted or improbable and the
use of relative reasoning rules to prioritize potentially
competing reactions. Predictions are terminated once an
external logP predictor deems that the molecule has become
sufficiently water-soluble to be excreted. The biotransformation
probabilities fall with decreasing lipophilicity as the ability of a
molecule to cross membrane boundaries and undergo further
biotransformations is reduced. Additional features of Meteor
include a link to a metabolism database where examples of the
biotransformation in the literature are reported with the ability
to filter on sequence length, enzyme and species. The creators
of Meteor note that despite the strategies described above
Meteor still tends to generate a high volume of false positives.
T h er e s u l t sg e n e r a t e ds h o u l db er e g a r d e da sp o t e n t i a l
metabolites requiring further analysis, an observation that is
generally true of all expert systems. They also make the
observation that biological factors are interdependent in a
nonlinear way rendering it a difficult problem to provide fail-
safe rules to encompass all metabolic transformations.
UM-PPS uses a classification system similar to Meteor and
biotransformations are classified as either very likely, likely,
neutral, unlikely, or very unlikely. Overprediction remains a
problem and further relative reasoning rules are used to rank
and prioritize predictions. The system is specific to microbial
catabolic metabolism and uses the University of Minnesota
Biocatalysis/Biodegradation Database (UM-BBD)
91 as a source
to generate the rules. The creators make similar observations to
Meteor, that definitive prediction rules applied to a wide region
of chemical space are hard to generate. They note that
predictions work best where query molecules show similarity to
those already in the database and where reaction conditions and
concentrations are similar to those documented. The system
tends to produce a wide range of predictions and so is more
suited to general environmental metabolism rather than when
applied to a specific microbial organism.
Some other systems use statistical analysis to evaluate a set of
biotransformation rules when applied to a data set. SyGMa
contains rules derived from inspection of the Accelrys Meta-
bolite Database with each rule assigned a probability score
relating to the number of correct predictions when applied to
the database. Metabolites are assigned the probability score of
the rule from which they were formed, allowing them to be
ranked. This enables a more finely grained view of probabilities
than the higher-level categorization performed in Meteor and
UM-PPS. To allow for greater differentiation and specificity in
predictions the rules are broken down into subsets and applied
to specific chemical reaction series.
TIMES
93 utilizes a comprehensive library of biotransforma-
tions and employs a heuristic algorithm to generate plausible
metabolic maps. Reaction rates from systematic and toxicity
testing are used to generate transformation likelihoods, other-
wise a combinatorial algorithm is used to translate known
metabolic maps taken from reference systems into best-fit
transformation probabilities.
Metabolizer
94 is a commercially available metabolism
prediction module which enumerates all possible metabolites
of a given compound and allows a prognosis to be made on
metabolic pathways, major metabolites and metabolic stability.
Besides human metabolism, it supports predictions on various
species including rat, bacteria, and plants.
Fingerprint-Based Data Mining Approaches. Meta-
print2D-React
21 is an extension of MetaPrint2D (see
“Predicting Sites of Metabolism”) that allows prediction of
the metabolites that are likely to be formed from a
transformation. SMARTS patterns are used to classify the
transformations on the basis of structural changes between
substrate and metabolite and occurrence counts for each type
of transformation are recorded. A separate occurrence ratio is
calculated for each type of transformation and the structures of
predicted metabolites are generated through reaction rules
using SMIRKS patterns. Predictions can be selected from
human, dog, rat or all species.
Combined Approaches. X-ray structures of CYPs indicate
that the position and orientation of substrates and their
metabolites are largely preserved. Consequently, metabolites
would be expected to match the chemical and geometric
constraints of the binding site, which would make them
distinguishable from decoy molecules for docking algorithms.
This is the hypothesis in recent work by Tarcsay et al.,
95 who
used the expert system MetabolExpert to generate putative
metabolites from known substrates. The docking program
GLIDE
53 was subsequently employed to reduce the false
positive rate. MetabolExpert was found to produce 74% of the
known metabolites using the default setup and 82% following
an enhanced rule set. Using the best setup for the combination
of MetabolExpert with docking as a postprocessing filter,
Tarcsay et al. report that their method is able to identify the
correct metabolite among the three highest-ranked structures in
69% of all cases.
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for selected CYP isoforms (see “Combined Approaches” in
section “Predicting Sites of Metabolism”).
■ THE CYP SUPERFAMILY OF METABOLIZING
ENZYMES
The CYP family of monooxygenase enzymes facilitate phase I
metabolism of endogenous and xenobiotic chemicals in many
organisms and bacteria. CYPs are classified into families and
subfamilies. Each family is indexed with a digit, a subfamily with
a letter and an individual gene with a digit. In humans, many
CYP isoforms exist, with CYP1A2, 2C9, 2D6, 2C19, 3A4, and
2E1 having been identified as playing the most significant roles
in drug metabolism.
Structure of CYPs. CYPs are predominantly composed of
α-helices, labeled A to L, commencing from the N terminus
(Figure 3). Helices F and G form the roof of the embedded
active site and between the I and L helices, lies the heme B
prosthetic group, which is also termed iron protoporphyrin IX.
This is present in all CYPs and provides the proximal ligand to
the heme via the sulfur on the cysteine. Protoporphyrin IX and
a small group of neighboring residues form a heme cradle
region, which is highly conserved.
Helix I has a highly conserved kink above the active site,
which may facilitate proton transfer. Otyepka et al.
96 have
described mammalian (families 2 and 3) CYP isoforms on the
basis of available crystal structures. An overview of available
X-ray structures for CYPs is provided in ref 97.
Generally, the available crystal structures have had two sets of
mutations carried out to facilitate their crystallization and
purification. Helices F′,G ′, F/G loop, and the N terminus
putatively make contact with the membrane region; hence, a
large hydrophobic transmembrane anchor at the N terminus is
replaced with a shorter, more hydrophilic chain. Second, a four
to five sequence polyhistidine-tag is inserted at the C-terminus.
It is generally accepted that such changes do not modify the
reactivity properties of the enzyme.
98
The active site volume of CYP isoforms varies as a function
of isoform. Cruciani et al.
99 investigated the structural char-
acteristics of the binding sites of various isoforms using GRID.
They point out the remarkable differences of the active site
volumes computed using a hydrogen probe. While CYP1A2
shows a site volume of 630 Å3, the binding site of the CYP3A4
model extends to 1500 Å3. They also ranked CYP isoforms by
the prevalence of hydrophilic regions in the binding pockets as
CYP2D6 > 3A4 > 1A2 > 2C19 > 2C9 and highlighted the
strong dependency of the hydrophilic patterns on protein
flexibility. Otyepka et al.
96 partitioned the mammalian CYPs
into three categories, starting with the largest: CYP2C5, 2C8,
2C9, 3A4 > 2B4, 2D6 > 2A6.
Various pathways from the interior active site, leading to the
solvent exterior have been identified. For a comprehensive
study making use of the CAVER
100 tool and a naming scheme
of these pathways the reader is referred to ref 101.
Reactivity of CYPs. Upon arrival at the active site, a
substrate will undergo chemical modification facilitated by the
heme iron’s unusual transient electronic state and the protein
environment. However, there is a set order to this process. CYP
functions within a catalytic cycle, with iron undergoing changes
in its spin state, oxidation number and ligand coordination
number as it proceeds around the ordered cycle. For more
detail, the reader is referred to the review of Shaik et al.
102 The
currently accepted mechanism is as follows. In its first state, the
resting state, Fe(III) is in a low spin, doublet state and is
hexacoordinated, with a water molecule occupying its distal
axial position. Arrival of a substrate displaces the axial water
leading to the formation of a pentacoordinate Fe(III) with a
sextet state. The change in redox potential associated with this
displacement allows it to accept an electron from a reductase,
nicotinamide adenine dinucleotide phosphate (NADPH)-P450,
thus forming the third state, Fe(II) that has a high spin state.
Molecular oxygen is then bound, yielding state four, a singlet,
oxy-ferrous complex. This singlet complex, readily accepts a
second electron from the reductase, resulting in the formation
of state five, a ferric-peroxo anion. The protein environment
facilitates the shuttling of a proton to form state six, which is
also referred to as Compound 0.
A second proton is accepted, followed by the heterolytic
cleavage of the molecular oxygen and loss of a water molecule
to form state seven, the electrophilic, high valence, iron-oxo
compound. This is the active species, analogously termed
Compound I, which then oxygenates the substrate. Next, the
product leaves the active site and a water molecule returns to
the distal axial position, completing the cycle.
Compound I is a ferryl-porphyrin-pi cation radical and has
three unpaired electrons (a triradicialoid). Two unpaired
electrons are localized on the ferryl group and the other is
shared between the sulfur on the covalently bonded cysteine
and the porphyrin. It is similar in all isoforms, and because of its
electronic structure being a function of its protein environment,
has earned itself the title of “Chemical Chameleon”.
103,104
Recent electron paramagnetic resonance (EPR) studies have
managed to provide experimental evidence for the long sought
intermediate, Compound I.
105
Molecular Dynamics Simulations on the Structure of
CYPs. Classical MD simulations of various CYP isoforms have
been used to gain insight into the proteins’ flexibility,
investigate channels into the active site, and generate ensembles
Figure 3. Structural overview of CYPs. Here, CYP3A4 (PDB 3NXU)
is depicted, with helical structures labeled A−L according to the
general scheme for CYPs.
96 The heme moiety is indicated in sticks
mode (red color).
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This first section focuses primarily on classical simulations used
to specifically study properties arising from system dynamics.
Simulations employed as a preamble to generating starting
QM/MM structures will be covered in the subsequent section.
Classical Parameters Developed for CYPs. Most modern
classic biological force fields have parameters for residues and
base pairs found in proteins and DNA; hence, modeling a
similar system can be easily accomplished. Entities that lie
outside of this chemical space, such as small organic molecules
or unusual residues, need special attention and additional
preprocessing to develop missing parameters. Usually, there is a
force field specific protocol for parameter development to
ensure that the new parameters are consistent with the rest of
the existing force field. Generally, parameter development
focuses on bonded and electrostatic terms. A corollary to this is
that a parametrization for a moiety within a specific force field
is not transferable to a different force field.
The heme B prosthetic found in CYPs is such a group and
various parameters for different force fields have been
developed over time. A further complication to this arises
due to iron’s changing electronic state as it proceeds around the
CYP catalytic cycle, since each state will have different classical
parameters.
102 A range of parametrizations for the heme B
prosthetic in CYPs have been carried out, some exclusively as a
parametrization process, others for use within a specific study
(Table 2).
In their study of the interaction of the P450cam isoform with
valproic acid, Collins et al.
106 developed a set of heme B
parameters for use with AMBER 3a. Schöneboom et al.
103
derived Chemistry at HARvard Molecular Mechanics
(CHARMM)
107,108 parameters for Compound I on the basis
of existing CHARMM heme parameters, by adding axial ligands
and updating charge parameters. Bathelt et al.
109 carried out a
similar process with the CHARMM22 parameter set. Oda et
al.
110 developed AMBER parameters for the pentacoordinate
Fe(III) in the sextet state, and Seifert et al.
111 reported AMBER
parameters for CYP in the Compound I state. Favila et al.
112
presented improved heme B parameters to carry out MD
simulations on CYP2C9 and CYP19 (also known as
aromatase).
Although not CYP parameters, the classical force field param-
eters for the heme C prosthetic developed by Authenrith et al.
113
for both the CHARMM and AMBER force fields provided a
foundation for derived CYP parameters by Skopalík et al.
114
(resting state) and Favia et al.
112 (ferrous low spin state).
Shahrokh et al.
115 have recently developed a set of AMBER
compatible CYP parameters, which are readily accessible in
their Supporting Information, for a range of heme states found
in its catalytic cycle.
Classical Simulations of CYPs. The majority of simulations
to date have been carried out with either the AMBER or
CHARMM force field, although some have also utilized
variants of the GROMOS or OPLS force field. All simulations
have made use of explicit water solvent and followed a standard
MD protocol. Recent simulations are on average 20 ns long, and
in a few cases, are an order of magnitude greater than this.
However, because simulation length is largely dictated by available
computational power, older simulations are shorter. Generally, the
simulations described here make use of a standard protocol for
condensed phase biological MD as outlined below.
A crystal structure usually provides starting coordinates, but
if there are missing residues or if a crystal structure is
unavailable, homology modeling methods may be used. Missing
hydrogens are then added. The correct protonation state of
certain residues at physiological pH is assigned according to
estimation of local pKa before finally assigning force field terms
to the system. Counterions are added to neutralize charge in
the system and to provide a solvent salt concentration that
reproduces physiological or experimental conditions as
appropriate. The system is placed under periodic boundary
conditions and Particle Mesh Ewald (PME) is used for accurate
treatment of long-range electrostatic interactions. Next, energy
minimization is carried out to relax any bad contacts between
protein and solvent, followed by short thermalization (allowing
the system to reach the desired temperature) and equilibration
MD phases, prior to the production simulation. In some cases,
extra biasing potentials or force field modifications may be
introduced, for example, to calculate the thermodynamics of
CYP binding site solvation and ligand binding, or to delineate
substrate access pathways.
During normal production dynamics, the backbone RMSD
relative to the original experimental or modeled structure may
be monitored over time to check that the protein is stable
under the influence of the simulation force field. Analysis
approaches may include the calculation of the per-residue root-
mean-squared fluctuation (RMSF), which provides a measure of
backbone mobility and can be directly compared to crystallo-
graphically derived temperature factors. Large concerted
motions may be identified using principal component analysis
(PCA; the result of diagonalization of a covariance matrix that
has been calculated from the dynamics), which filters out rapid
thermal atomic fluctuations. Finally, the molecular details and
energetic interactions between protein, ligand, and solvent may
be analyzed, supplemented by visual analysis of the trajectory.
Early simulation studies focused on the local structure/
dynamic relationships associated with alternative ligand binding
modes in CYP isoforms. Wade and et al. created a series of
camphor analogues designed to fill an empty region of the
substrate binding pocket of P450cam and a mutant, and
experimentally measured thermodynamic properties of binding
were rationalized via substrate−protein/solvent interactions
observed in MD simulations.
116 The same group applied
multicopy MD simulations, in which several ligands are
simulated in the presence of a single protein to locally enhance
sampling, to explore multiple ligand binding modes of different
enantiomers of camphor in P450cam, revealing differences in
binding modes for similar but chemically different ligands.
117
The structural reorganization associated with differential
substrate selectivity in CYP17 isoforms from various species
has also been investigated via MD simulation approaches.
118
Moreover, simulations of a CYP2A4 model has helped to
rationalize key interactions with active site residues shown via
mutation to determine specificity for testosterone metabolism
(in contrast with CYP2A5).
119 Strobel et al.
120 used simulations
to provide a molecular explanation for the observation that
inactivators are able to discriminate between the closely related
CYP P450 isoforms 2B4 and 2B5 in terms of differential
stabilities of inhibitor binding orientation.
Several simulation studies have sought to provide a molecular
basis for the promiscuous nature of substrate specificity
exhibited by CYPs in terms of their dynamics. Park et al.
121
used nanosecond-time scale MD simulations of CYP3A4 to
propose that the high-amplitude flexibility of a loop near to an
egress channel in the apo state (but damped when bound to a
substrate or inhibitor) may be responsible for the enzyme’s
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122 generated 200
ns trajectories of the thermophilic P450 CYP119 enzyme,
providing evidence for a flexible conformational selection
mechanism in substrate binding, and revealing from an analysis
of correlated motions that the active site moves relatively
independently from the rest of the protein, leading to
“insulation” from external dynamics.
123 S e i f e r te ta l .
111
examined the interaction of CYP2C9 with its substrate,
warfarin, using an AMBER FF99 model with their own heme
B parameters. Multiple 5 ns trajectories were run and they
observed a stable protein core and a mobile surface that gave
rise to two channels, and concluded that this leads to a broad
substrate profile with high regioselectivity. Sano et al.
124 studied
three polymorphisms of CYP2C9 which involved the mutation
of a single amino acid residue, using MD and docking methods,
and related catalytic activity to deformations of this pocket.
Skopalík et al.
114 carried out simulations on three members
of CYP3A4, 2C9, and 2A6. In addition to the standard MD
simulations of each isoform, a MD run was carried out at 398 K.
High temperature simulations enable a more extensive
sampling of protein dynamics, and have previously been used,
for example, to understand the origins of stability of the
thermophilic and barophilic CYP119 enzyme via nanosecond-
time scale simulations.
125 An analysis of the dynamics of the
three isoforms revealed that CYP malleability is directly related
to substrate specificity. CYP2A6 was the most rigid investigated
CYP and consequently has a narrow range of substrates, while
CYP3A4 was the most flexible and most promiscuous analyzed
CYP. They also identified ten flexible regions and a rigid core as
well as a malleable distal side and a less flexible proximal side.
Such observations could not be concluded from previous X-ray
structure analyses, as a comparison of calculated and
experimental B-factors confirmed that protein dynamics are
damped in the presence of crystal lattice contacts.
CYP substrate specificity and associated conformational
flexibility has also been investigated via combined simulation
and experimental approaches. A flexible loop around the active
site has been observed in a CYP2C9 mutant, leading to a more
open conformation consistent with spectroscopic data.
126 In
another study, NMR-derived residual dipolar couplings were
incorporated via torsional restraints within MD simulations of
P450cam to identify a more open and accessible active site with
a wider range of substrate orientations than those observed
crystallographically.
127 Sigmoidal behavior in kinetic studies led
Fishelovitch et al.
128 to examine the possibility of cooperative
binding between two substrates. They modeled diazepam in
CYP3A4, comparing simulations of this with the substrate-free
state, and concluded that F304 on the proximal I helix plays a
key role in the mechanism of co-operativity between substrate
molecules.
Significant effort has been devoted to understanding the
properties of internal CYP solvation. While the volumes of the
active sites of different CYPs vary significantly, they have been
shown to contain water that must be displaced upon substrate
binding, and this must be considered when attempting to
calculate the binding free energy of a particular substrate.
Moreover, the reactivity of the active site is dependent upon
water. Displacement of water favors the ferrous Fe(II) state and
prevents electron uncoupling,
129 while water “wires” may relay
proton transfers needed for heterolytic cleavage of dioxygen.
Only limited information regarding water occupancy may be
extracted from crystal structures, necessitating complementary
simulation approaches. Several factors contribute to this issue,
such as conformational flexibility of the protein, the difficulty of
cryoprotection schemes, as well as the disordered nature of
solvent molecules.
The simulations of Skopalík et al.
114 enabled observation of
water exchange between the active site and bulk solvent, with
the number of water molecules reaching a dynamic equilibrium
after 1.5 ns. Analysis of access/egress channels (pw2e and
pw2c) identified a solvent channel. In a more recent analysis,
Hendrychová et al.
130 examined the effect of high pressures
(300 MPa) upon CYP1A2, 2A6, 2C9, 2D6, and 3A4 both by
experimental spectroscopy and molecular dynamics simulation.
Using a similar protocol as in their previous paper, they found
that with increased pressure, the flexibility of the CYPs
decreased and the number of water molecules in the active
site increased, with the exception of CYP3A4. They also
concluded that of the five CYPs examined, CYP2A6 and 1A2
have the least malleable active sites.
Because of the relatively long time scales required to observe
water exchange between internal cavities and bulk solvent,
Helms and Wade
131 implemented a pioneering “alchemical”
MD approach, in which a water molecule is gradually
annihilated in bulk solvent and another is inserted into the
protein cavity, enabling calculation of the relative free energy of
hydration of the CYPcam active site via a simple thermody-
namic cycle. This revealed that hydration by around six water
molecules was thermodynamically most favorable, in agreement
with experimental estimates, suggesting the active site water
density is about half that of bulk solvent. Recent improvements
in computational power enabled Miao and Baudry
132 to
observe the unbiased water diffusion into and out of the active
of P450cam over a 300 ns trajectory, confirming that on
average, six water molecules are found in the camphor-free
active site. However, between 0 and 12 water molecules could
be present at any given time because solvent exchanged rapidly
with bulk solvent via multiple channels identified with the
CAVER
100 tool. Rydberg et al.
133 also showed that active-site
waters could exchange with bulk during 4 ns simulations of six
mammalian CYPs. The mean number of waters and exchange
pathways varied significantly between isoforms, consistent with
the variability in active site volume.
99
MD simulations have also been utilized to study the effect of
organic cosolvent molecules such as DMSO on the structure
and dynamics of CYPs
134,135 for commercial exploitation, since
many industrially important substrates are poorly soluble in
water. Moreover, a series of 1 ns MD trajectories have been
used to identify docking sites for CO binding to P450cam,
rationalizing laser flash photolysis data.
136
Because the active sites of the CYP, enzymes are substantially
buried within the protein structure, specificity and kinetics are
likely to be directly linked to the passage of water, substrates,
and products into and out of the protein. For this reason, much
focus has been placed on the identification of static or dynamic
channels that connect the active site to the protein surface.
Available crystal structures yield a wealth of information
regarding access/egress channels,
101 but simulation approaches
can complement this by providing insight into the dynamics
and energetics of substrate passage. For example, Fishelovitch
et al.
137 identified a gated water pathway and an additional
substrate channel in CYP3A4 using their MolAxis tool.
138 A
second MolAxis channel study on the same isoform
139
examined cooperative binding of ketoconazole and ligand-
induced conformations changes. The authors also identified
various bottleneck residues, and concluded that two channels
Journal of Chemical Information and Modeling Perspective
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Haider et al.
140 identified three channels that converged on the
heme in a homology model of CYPC17, identified using the
MOLE tool.
141 MD simulations demonstrated different
substrate binding modes, and a correlation between low
vibrational modes and active site gating was demonstrated.
Accelerated MD approaches have also been developed to lower
the energy barriers between different crystallographically
identified open and closed conformational states of P450cam,
providing insight into the likely mechanisms of ligand
binding.
142
The direct observation of ligand/product entry/exit is
generally not possible using typical MD simulations due to
limitations in accessible time scales. As a result, a variety of
“biased” simulation approaches have been utilized to enhance
sampling of ligand egress within CYPs.
143 The Wade group
developed the random expulsion MD method, involving the
application of a randomly oriented artificial force to an initially
bound ligand, to identify channels in three bacterial CYPs.
144
Steered MD, in which a constant force is applied to a virtual
spring attached to a molecule along a predefined vector, was
subsequently used to drag ligands along each channel. A
minimization-based approach identified a channel common to
all three bacterial CYPswith specific channel features in each
isoform adapted for their respective substrate/product
specificityas the most likely route of ligand passage.
145 A
similar approach was applied to a mammalian CYP2C5 enzyme
and used to propose that hydrophilic substrates and products
may pass through one channel, whereas lipophilic substrates
may enter via a channel embedded within the membrane.
146
This was recently supported by the first reported MD
simulations of a full-length mammalian CYP inserted within a
lipid bilayer.
147 Coarse grained simulations were used to
efficiently sample various orientations of the membrane-bound
CYP, providing the starting point for subsequent all-atom
simulations. Correlations were found in the permittivity of
putative ingress and egress tunnels, and the presence of the
membrane stabilized the open state of an internal aromatic gate
in the previously identified channel connecting the active site to
the bilayer phase.
The steered MD method and its variants have been applied
to a number of other CYP systems including CYP2B1
148,149
and CYP3A4,
150−152 enabling the identification of possible
channels and associated rupture forces during ligand passage,
and to probe interactions with key residues identified by site-
directed mutagenesis. As it becomes easier to generate longer
time scales and steered MD simulation ensembles, it has even
become possible to estimate the free energy pathways
associated with ligand entry and egress.
153
Molecular Dynamics Approaches for the Calculation of
Affinity of Substrates and Metabolites. As well as providing
qualitative information concerning protein−ligand interactions,
a number of methods within the MD simulation framework
may be utilized to directly estimate ligand binding energies.
Although this tends to involve greater computational cost than,
for example, docking, the results are normally more reliable due
to the use of an accurate physical force field and extensive
conformational sampling (if sufficient starting points are
included). In more or less all the approaches, calculation of
the ligand binding free energy (ΔG) relies on the observation
that its value is a state function and is hence dependent only on
its initial energy in solution and final energy following binding.
Thus, a thermodynamic cycle may effectively be invoked, considering
either the “transfer” of a ligand into solution and into the
protein binding site, yielding the absolute binding energy, or
the transfer of two different ligands to the binding site, yielding
the relative binding energy.
For example, Åqvist et al.
154 devised the semi-empirical linear
interaction energy (LIE) technique to estimate ligand-protein
binding energies. In contrast with some more rigorous
approaches (see below), only the physically relevant protein-
bound and free solvated states of the ligand (i.e., the “corners”
of the thermodynamic cycle) are considered with LIE,
necessitating just two MD or Monte Carlo simulations.
155
From the equilibrium ensemble of nonbonded interaction
energies between the ligand and its surroundings for these two
states, ΔG may be calculated as an empirically weighted
difference between the average bound and unbound energies.
There are separate scaling coefficients for the nonpolar and
electrostatic interactions and an extra independent constant
may be included. While default values for these parameters are
available, they are often optimized using a training set. Good
correlation between experimental and calculated binding
energies has been demonstrated in many cases when utilizing
LIE, particularly for related series of ligands, and as early as
1996, it was shown that the approach could be successfully
applied to the estimation of relative and absolute binding free
energies for a range of substrates in P450cam.
156
Vasanthanathan et al.
157 investigated ligand binding affinity
of thirteen ligands with CYP1A2 using a LIE-based method.
GOLD was initially used to place the ligand in the active site,
followed by a standard MD protocol using the GROMOS 45A4
force field, totaling 1 ns of NPT production dynamics. From
this trajectory ΔG was calculated using LIE. For comparison
and validation, experimental IC50 values were converted to
equilibrium constants (Ki), which in turn were used to estimate
ΔG. They demonstrated a linear correlation between
experimental and calculated values with a RMSD of 2.1 kJ/mol,
and concluded that the van der Waals interactions dominated
over the electrostatic interactions.
Karlsson et al.
158 constructed homology models of 26A1 and
26B1 and various ligands, including five retinoic acid
metabolizing blocking agents (RAMBAs), which were docked
into each respective site, followed by 0.5 ns of NVT MD
simulation. The LIE method was used to calculate values of
ΔG, which were compared to experimental IC50 values. The
authors concluded that the homology models could distinguish
between strong and weak inhibitors and identified various
important residues in the active site.
Stjernschantz et al.
159 developed an iterative protocol
employing multiple MD simulations accounting for an
ensemble of generated docking poses. The approach was
tested on a set of 12 known binders of CYP2C9, and the
RMSD for predicted binding affinity was 2.9 kJ/mol. It was
shown that this technique is able to lower the impact of the
initial pose selection and it also takes into account the
possibility of multiple binding modes.
Despite these reports, which often demonstrated impressive
correlation between experimental and calculated ΔG, the
inherently empirical nature of LIE may be undesirable in
some cases. An alternative is to use “computational alchemy”,
which includes related methods such as free energy perturba-
tion (FEP) and thermodynamic integration (TI). Such formally
correct approaches tend to be computationally demanding but
have the capacity to yield highly accurate relative or absolute
ligand binding free energies, in principle limited only by the
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tional sampling.
160
The key feature of alchemical methods is that the
configurations sampled between different states should have a
significant degree of “overlap”.
161 Thus, unlike in LIE where
two ensembles must be generated, a multistep approach must
be used, in which a path between the “corners” of the thermo-
dynamic cycle (see above) is sampled. Practically, this is nor-
mally implemented by introducing a series of intermediate
potential energy functions constructed as a linear combination
of end states. Thus, one ligand is alchemically transformed to
another (to yield the relative ΔG) or a ligand is alchemically
“annihilated” (for the absolute ΔG).
Wade et al.
131 utilized an alchemical MD approach to
calculate the relative ΔG of water molecule binding to the
CYPcam active site and later extended this work to couple
the exchange of six high-occupancy water molecules to the al-
chemical transformation of camphor inside the active site,
yielding an accurate measure of its ligand binding ΔG.
162 Deng
and Roux
161 pointed out that this strategy required prior
knowledge of the solvation properties of the cavity in question.
They therefore recently implemented a novel approach
combining alchemical MD for ligand-binding ΔG calculation,
with a grand canonical Monte Carlo algorithm, enabling the
number of waters to vary freely during the simulation. This
yielded extremely accurate estimations for the thermodynamics
of camphor binding to P450cam,
163 and the method should be
generalizable to any CYP site. It is clear that careful con-
sideration of CYP solvation properties is necessary, even when
combining MD with more empirical approaches to binding
ΔG calculations.
157
QM/MM Approaches with CYPs. Classical simulations can
yield information about dynamics and conformation changes.
However, this level of theory does not have the ability to
represent bond breaking or making processes, whereas a richer
quantum mechanical treatment of all the electrons within the
system is still too computationally demanding.
A common approach is to partition the calculation into two
regions that are treated at different levels of theory. Generally, a
small quantum mechanical region is defined around the active
site, where bond breaking is presumed to occur, and the rest of
the system, usually the rest of the protein and bulk solvent, is
treated classically. The two regions are not independent but are
coupled. For example, the wave function in the QM region will
be polarized by the influence of the point charges in the
classical MM region, and conversely, the MM region will be
influenced by a nonstatic point charge distribution emanating
from the QM region. Many coupling methods exist and the
QM/MM approach can be used to calculate single point
potential energies or gradients can be evaluated for the system
to be propagated dynamically (QM/MM MD).
The Thiel group has published several excellent papers
characterizing the dynamics and catalytic mechanism of CYPs.
Their work includes investigations on polarization and hydro-
gen bonding effects of the protein environment on Compound I.
103
They carried out 215 ps of MD using their protoporphyrin IX
parameters to generate snapshots for subsequent QM/MM
calculations and concluded that it transformed from a sulfur-
centered radical to a porphyrin-centered radical cation. Further
studies from this group include the QM/MM-based analysis of
the C−H hydroxylation mechanism
164 and the theoretical
investigation of the Compound I reactive intermediate.
165 This
and additional work is discussed in their comprehensive review
102
on the structural properties, reactivity, and substrate selectivity
of CYPs analyzed by QM/MM approaches, and therefore, we
provide here a brief summary on this topic.
Starting configurations are usually generated from a classical
MD simulation. A QM/MM hybrid approach is used whereby a
truncated porphyrin (both propionate groups are removed)
and a truncated cysteine (S) is set as the QM region. In the
QM region, an UB3LYP method is used with the Los Alamos
effective core potential and associated triple-ζ contracted basis,
LACVP, on Fe and the 6-31G(d) basis on the remaining QM
atoms.
166
Bathelt et al.
109 examined the electronic properties of
Compound I and concluded the lowest electronic state to be
a near degenerate pair of doublet/quartet optimizations of A2u
states, with two unpaired electrons localized on the Fe−O and
the other delocalized on the porphyrin and thiolate ligand. In a
later study,
167 they examined the mechanism of benzene
hydroxylation facilitated by CYP2C9 and found that the energy
barrier for the addition step is comparable to the experimental
rate constants of the same family member, CYP2E1. They also
compared the energetics of benzene approach toward the side
or face (relative to the porphyrin plane) and concluded that
these arene addition pathways are both accessible.
Fishelovitch et al.
168 explored the effect of a substrate on
Compound I, showing that in a substrate-less Compound I
state, the Fe−S bond elongated and localized the radical on the
sulfur. Conversely, the presence of substrate shortened this
bond.
Sen et al.
169 studied the dynamics of CYP51 with specific
reference to the proton shuttling involved in the molecular
oxygen activation. They conclude that the protein environment
is important in tuning the electronic structure of intermediates
and highlighted the range of proton shuttling routes within the
CYP family. The study also demonstrates opportunities for
experimental validation because much experimental data is
available for the peroxo intermediate.
Lonsdale et al.
170 investigated the chemoselectivity of alkene
oxidation with CYP101, finding that QM/MM reaction barrier
heights were in qualitative agreement with experimental
selectivities. Given the accessibility of both hydroxylation and
epoxidation to the ferryl oxygen, it is the relative reactivity of
Compound I that determines the relative ratio of products.
Attention is also drawn to the complexities of such modeling
and the need for a wide ensemble of starting geometries for
QM/MM approaches. In a different study,
171 the same authors
demonstrate the importance of a dispersion correction for
B3LYP methods in the study of CYPs. Their work showed that
inclusion of dispersion has a significant effect on the energies
and geometries of transition states and encounter complexes.
Furthermore, an improved agreement with experimental data
was observed compared to their original CYP101 study.
170
Li et al.
172 conducted a QM/MM study of CYP2A6 on (S)-
(-)-nicotine. From calculating a minimum QM/MM energy
path they determined a reaction mechanism: initial abstraction
from the 5′-position to the oxygen on Compound I followed by
an O-rebound step, the recombination of the nicotine moiety
with the iron hydroxyl to produce the 5′-hydroxynicotine
product. They conclude that nicotine exists in a less favorable
protonation state when undergoing CYP catalysis.
The reaction mechanism of the conversion of tyramine to
dopamine, as catalyzed by CYP2D6 was examined by Schyman
et al.
173 The traditional Meisenheimer complex mechanism, i.e.,
direct aromatic hydroxylation, was ruled out on the basis of
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entirely dictated by the local electric field of the protein
environment. An initial phenolic H-abstraction of the
protonated tyramine by Compound I is followed by a phenoxyl
ring rebound, culminating in a keto−enol rearrangement to
dopamine, outside of the protein. Interestingly, in this QM/MM
study, the authors found that only a 3 Å radius sphere of the
charges from the MM environment needed to be included in
the QM/MM model for the H-abstraction intermediate to be
stabilized to a value comparable to that of the full QM/MM
model.
The mechanism of H-abstraction, followed by O-rebound is
common between these two simulations. However, the
tyramine is in a protonated state (protonated amino tail),
whereas nicotine is in its unfavorable free base state.
A more recent study by Lonsdale et al.
174 investigated the
electronic structure of the Compound I state between different
CYP isoforms using a QM/MM approach, with the Compound
IF e −O bond enthalpy as the comparison metric. Interestingly,
they find that there is little variation between the three isoforms
they examined, and significantly more variation within a single
isoform’s ensemble of MD generated structures. They conclude
that the hydrogen bonding, the polarizing environment and
thermal fluctuations influence Compound I’se l e c t r o n i c
structure and stress the importance of using an ensemble of
structures in QM/MM studies. They also state that the
substrate’s presence in the cavity alters the electronic structure
of Compound I. It reduces the number of hydrogen bonds that
ferryl oxygen has to the water solvent, increasing the spin
density on ferryl oxygen, thus weakening the Fe−O bond.
Predicting Interaction of Xenobiotics with CYPs.
Interaction of xenobiotics with metabolizing enzymes is likely
to lead to substantial changes in biological effects, potentially
causing a loss of activity or toxic effects. CYPs are key
metabolizing enzymes, accounting for approximately 75% of
total metabolism.
175 They play a pivotal role in drug
metabolism, where seven of the 57 known human CYP
isoforms facilitate more than 90% of the metabolism, as well as
DDIs.
176 Polymorphism of certain CYP isoforms such as
CYP1A2, 2D6, 2C9, or 2C19 add another layer of complexity
to the problem.
177−179 Because of the wide range of
metabolism rates observed for xenobiotics, determination of
the kinetic profile and optimization of dosing (to remain within
the therapeutic window) becomes an even more challenging
and sometimes impossible task. Mutations of metabolizing
enzymes and their impact on the kinetics of drug molecules are
difficult to predict and would require a substantial computa-
tional effort for each compound and CYP. Consequently,
prevention of interaction of compounds with polymorphic
CYPs by rational design is a favorable strategy.
Predicting DDIs is a nontrivial and complex problem that has
been traditionally addressed in elaborate clinical studies.
180
Even for the extrapolation of in vitro assay data to in vivo effects
some major uncertainties and controversies exist.
181 Several in
vitro CYP inhibitors, such as clotrimazole and other compounds
sharing an imidazole scaffold, have been observed to induce
these proteins in vivo.
182 One major challenge in predicting
systemic effects derives from the crosstalk of receptors
regulating metabolizing enzymes.
183 Though in vitro assays
are becoming more readily available and more and more insight
on the mechanism of inhibition and induction of metabolic
enzymes has been gathered, a complete framework that would
allow the accurate prediction of enzyme inhibition and induction is
still missing.
5 Here, we provide an overview of computational
methods aimed at (among other functions) the prediction of
interactions between xenobiotics and CYPs. For more detail,
the reader is referred to refs 7, 184, 185.
Predicting CYP Inhibition by Xenobiotics. CYP inhibition is
in general considered to be more problematic than CYP
induction. CYP inhibition may cause toxic effects by an increase
of activity at targets and antitargets and is commonly evalu-
ated by determining the inhibition constant, Ki, using liver
microsomes or cDNA-expressed microsomes.
179 CYP induc-
tion is a central focus for drug safety, potentially leading to a
loss of therapeutic efficacy due to increased metabolism rates
but also to an increased production of toxic metabolites (see
below).
“QSAR and Machine Learning Methods”. MD simulations
are typically able to deal with previously unseen ligand-target pairs
when attempting to predict metabolic sites on small molecules
or their binding affinity (see “Molecular Dynamics Simulations
on the Structure of CYPs”). However, they are at the same time
computationally demanding and, consequently, they are not
always applicable, particularly when time is at a premium. In
real-world situations, very often an interactive, “immediate”
prediction of the likelihood of being a substrate or an inhibitor
of particular CYPs is desired, for instance, when medicinal
chemists are interactively designing a series of structures.
QSAR, machine learning, and other approaches are in many
cases well suited to provide this kind of instant feedback to the
user. At the same time, they are both based on prior knowledge.
Hence, their main shortcoming is, generally speaking, their
limited extrapolation ability to novel chemical series or
molecules outside of their applicability domain.
QSARs attempt to derive quantitative relationships between
the structure of a compound and its activity. Those relation-
ships are based on the principle that the chemical structure of
compoundsand similarities and trends of a chemical series
are related to the molecular properties exhibited.
186 Hence, in
order to generate relationships between structure and function,
a way to describe the molecule is needed (see ref 187 for a
recent review), as well as a suitable statistical or machine
learning method
188 to generate the particular SAR of interest.
Activity in the particular context of this review means the
inhibition of one or more metabolizing enzymes, in particular
isoforms of the P450 enzymes by a small molecule, or its ability
to act as a substrate of these enzymes.
What is remarkable about the area of QSAR in metabolism
and also in toxicology is that guidelines for the validation of
models have only relatively recently been published, as part of
the Organisation for Economic Co-operation and Development
(OECD) and European Union efforts to reduce the amount of
animal testing performed in the context of exploring properties
of novel chemical entities (NCEs). In order to trust QSAR
modelswhich are essentially computational predictions of
molecular propertieswithout resorting to experiment in every
single case, requires validation and tests of robustness and is
fundamental in order to gain trust in the models. In this
context, it might be useful to consider a recently published
summary of requirements pertaining to a practically useful
QSAR model as follows (according to OECD guidelines): “The
guidelines recommend that QSAR models should be associated
with (i) a defined end point, (ii) an unambiguous algorithm,
(iii) a defined domain of applicability, (iv) appropriate
measures of goodness-of-fit, robustness, and predictivity, and
(v) a mechanistic interpretation, if possible”.
189,190 Certainly,
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trustworthy QSAR model upon which important practical
decisions will be based.
The term “QSAR” does not immediately define which
mathematical methods are used to derive those SARs. They can
be statistical models or more complex machine learning models
such as SVMs,
191 random forests,
192 and similar approaches. In
the following, we will discuss approaches to predict CYP
inhibitors and substrates using conventional (statistical)
structure−activity modeling methods as well as machine
learning methods applied to the area. Apart from reviewing
work directly, the reader is also referred to previous reviews for
further information, namely those focusing on QSAR modeling
applied to CYP metabolism
178,184,185,193,194 as well as those
focusing on the machine learning approaches to the
field.
178,195−198 What is also remarkable is that in the field of
metabolism or ADME/Tox prediction in general, “open” (free
and often open-source) approaches are making progress, in
tandem with public bioactivity databases,
199 etc. The reader is
referred to a recent review of the field for an overview of many
of the current available tools.
200
Approaches to classify or quantify the interaction of chemical
compounds with members of the CYP family can also be
differentiated depending on how data is analyzed. Models can
be generated for either inhibitors, substrates, or most generally,
“ligands” or interaction partners of the enzyme. They can be
either global or local, depending on the size and nature of the
data set. While global models are built on large and diverse
collections of compounds and therefore have a large domain of
applicability, local models are specialized to a very specific
chemical and biological space. Global models generally
maintain their performance when predicting more diverse
molecules (and properties), while local models may show
superior prediction accuracy within the chemical space they are
trained on.
Models can be either trained on molecules with measured
activities for a whole enzyme family or for a specific isoform.
Most challenging for the development of models is the fact that
biological data such as IC50,K i, and Km values depend very
much on the experimental conditions (these are indeed
different experimental measures which are often, through the
sparsity of data, combined in single models), which leads to a
significant variance in the data. Good models may thus be able
to explain 65−85% of the variance in a data set. Models
reported with higher accuracy are very likely to be overfitted.
Furthermore, different parameters can vary from model to
model, such as the composition of the training set, the
validation method, the choice of descriptors, and last but not
least, the mathematical modeling method employed to generate
SARs. Here again, models may be based on categorical or
continuous variables. All of the above factors generally differ
between models to be compared, and this needs to be kept in
mind when relating the performance of models to each another.
For more information on modeling toxicity data and its
challenges, the reader is referred to a recent review.
201
Classification Models. As an example of a relatively typical
classification study, k-nearest neighbor, decision trees, random
forests, ANNs, and SVMs using different kernels were
employed to predict substrates, inhibitors, or “interactors”
with the CYP1A2, 2D6, and 3A4 isoforms on the basis of a set
of 335 structurally diverse compounds.
202 A total of 188
descriptors such as atom counts, charge properties, and
connectivity indices were used for model building, employing
10-fold cross validation as a model validation method.
Classification performances of 81.7−91.9% for CYP1A2,
89.2−92.9% for CYP2D6, and 87.4−89.9% for CYP3A4 were
obtained. Interestingly, in this work various decision tree
methods were found to outperform “numerical” methods such
as SVMsa result that seems not to hold when applying these
algorithms to larger data sets.
203
While single metabolizing enzyme predictions are easier to
perform from the computational side, they do not reflect the
situation that in reality many compounds are metabolized by
more than one enzyme. To reflect this situation, in a more
recent study
204 a total of 580 CYP substrates of seven different
isoforms have been analyzed by applying multi- and single-label
classification strategies, including SVMs, multi-label k-nearest
neighbor classifiers, as well as ANN modeling methods. While
single-label and multilabel classifiers at first sight seem to
achieve similar performance, the authors state that “the multi-
label approach more coherently reflects the real metabolism
information”, namely, that compounds are in many cases
metabolized by different CYP isoforms, though at different
rates and giving rise to different metabolites. In this particular
case, out of the 580 compounds 488 were metabolized by a
single CYP isoform, while the remaining 92 structures are
metabolized by up to five enzyme variants.
The idea of having “true negatives” in a data set is also critical
to address. However, compounds of unknown activity are often
treated as “putative inactives”. This was however approached
explicitly in a recent study where for CYP3A4, 2D6, and 2C9
inhibitors and substrates were analyzed using SVMs.
205 For the
prediction of inhibitors, only CYP3A4 and 2D6 were used, but
substrate models have been generated for all isoforms. In
particular, two consensus SVM methods, namely, “positive
majority” and “positive probability” were employed in this work
on a large data set comprising several hundred activity data
points. In addition to the inhibitors and substrates, likely “non-
inhibitors” and “non-substrates” were generated. The model
obtained accuracies for classification of substrates and non-
substrates, respectively, of 98.2% and 90.9% for CYP3A4, 96.6%
and 94.4% for CYP2D6, and 85.7% and 98.8% for CYP2C9.
Regarding the different machine learning methods employed,
the consensus support vector machine methods were generally
found to give better performance than those based on single
SVM classification systems.
In many cases, data sets are not balanced, which poses
additional challenges when developing machine learning
models. In a recent study using CYP2D6 inhibitors,
206 a set
of 185 training and 78 test data points were employed using
“ensemble” descriptors (containing atom counts, constitutional
descriptors, topological descriptors, etc.) in combination with a
SVM. In this work, the influence of various oversampling and
“threshold moving” techniques on classification performance
was investigated and overall it was found that employing
oversampling and threshold moving indeed had a positive
impact on obtaining accurate classifiers.
isoCYP
207 is a software tool for the prediction of human
CYP isoform specificity based on the work of Terfloth et al.,
208
who developed a number of classification models using multino-
mial logistic regression, decision trees and SVM. The models
are trained on a set of 146 compounds known to be metabo-
lized by human CYP3A4, 2D6, and 2C9 isoforms and the models
were evaluated using an external validation data set comprising
233 compounds. The best model obtained a leave-one-out
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external validation set.
Another study employing SVM to identify and classify
substrates of CYP1A2, 2C9, 2C19, 2D6, and 3A4 is based on a
17000 compounds data set from the National Institutes of
Health Chemical Genomics Center (NCGC).
209 Classification
models obtained area under the receiver operating character-
istic (ROC) curves equal to or higher than 0.85 for any of the
investigated CYP isoforms.
Quantitative Models. While classification models are
sometimes preferred to numerical/regression models since
they often have superior performance in validation experiments
when only class labels are required, they are generally not able
to make affinity predictions, which are at least in relative terms
often needed when considering competing interactions in
biological systems. Some of those quantitative models relating
to metabolism prediction shall be discussed below.
Classical Quantitative QSAR Models. Lewis et al.
210 es-
tablished quantitative models for ligands for a total of six P450
isoforms, namely, CYP1A2, 2B6, 2C9, 2C19, 2D6, and 3A4. In
this work, the authors obtained correlation coefficients ranging
from R = 0.94 to 0.99 between predicted and experimental
P450 binding affinity, which in this case included a mixture of
Km,K d,o rK i values. They found that including hydrogen
bonding parameters in the QSAR analysis in combination with
the number of pi-pi stacking interactions was crucial for model
performance. Hence, given that interpretable variables were
employed in the model in the first place, knowledge about
interactions could also be derivedto some extentfrom the
resulting model.
For the isoforms CYP2D6, 1A2, 3A4, 2A6, 2C9, 2C8, 2C19,
and CYP17, PLS regression as well as 18 machine learning
methods as implemented in WEKA
211 were recently employed
on a data set comprising a total of 797 ligand−CYP IC50 data
points.
212 PLS regression as a baseline method was employed
on a subset of six and 15 selected descriptors, respectively.
From the resulting models, R2 values from 0.69 to 0.94 were
obtained for the six-descriptor subset, and from 0.78 to 0.99 for
the set comprising 15 descriptors, respectively. However, a
particular modeling technique, namely PLS “with mixed-integer
linear programming-based hyperboxes”, was able to improve
upon those results using only six descriptors. The method
involved homology modeling, docking, and finally ligand-based
classification steps, which likely renders it time-intensive in
practice. Also the descriptors selected to be the most significant
are largely noninterpretable connectivity indices, which are not
generally intuitively related to metabolic mechanisms.
In a similar fashion, the way data for CYP inhibition or
substrate-likeness data are obtained experimentally can have a
profound impact on the performance and applicability of CYP
SAR models. In a recent study,
213 the data sets consisted of
marketed drugs and drug-like compounds, all tested in four
assays measuring the inhibition of the metabolism of four
different substrates by the CYP3A4 enzyme, benzyloxycoumar-
in, testosterone, benzyloxyresorufin, and midazolam. It was
found that by employing only a single one of the four data sets
no reliable inhibition model could be generated. On the full
data set, however, a multiple pharmacophore hypothesis could
be developed which was able to model promiscuity, in
particular the CYP3A4 isoform of the CYP family. Hence,
care should be paid not only to the statistical model validation
method employed, but also to the data used to generate models
for P450 activity.
As a commercial software provider, ACD has a software suite
on the market that is able to make regioselective predictions of
metabolic transformations in its P450 Regioselectivity Mod-
ule.
214 On the basis of more than 900 training set compounds,
every atom is assigned a likelihood of undergoing one of five
possible transformations, namely N-dealkylation, O-dealkyla-
tion, aliphatic hydroxylation, aromatic hydroxylation, S-
oxidation. A reliability index for the prediction is provided,
depending on the similarity to the training set atoms as well as
the consistency of metabolic transformation information.
Optionally, isoform-specific predictions can also be performed
for CYP3A4, 2D6, 2C9, 1A2, and 2C19 using additional
software modules. However, to the knowledge of the authors
no standardized validation of the tool has been publicly
disclosed.
In silico tools using different machine learning methods have
been derived for various enzyme isoforms. For the CYP2D6
and 2C9 isoforms, multidimensional QSAR has been employed
to quantify the binding affinity of 56 compounds and 85 com-
pounds, respectively, to their metabolizing enzymes.
215 In this
study, a cross-validated R2 of 0.81 and 0.69 was obtained, and
models were validated by different methods including Y
scrambling and an additional external test set. This model is
also available publicly at VirtualToxLab, which combines
multidimensional QSAR with a flexible docking approach.
216
VirtualToxLab supplies QSAR models for 16 proteins known
or suspected to be responsible for adverse drug effects, including
AhR, androgen receptor (AR), estrogen receptor (ER), etc., and
reports a calculated toxic potential.
216 It was used to predict the
toxic potential of more than 2000 xenobiotics and chemicals and
to estimate the binding affinities of anthracene- and steroid-based
compounds on various CYP isoforms and on AhR (see below).
3D-QSAR and Molecular Interaction Fields. 3D-QSAR
analyses such as Comparative Molecular Field Analysis
(CoMFA),
217 GRID/Generating Optimal Linear PLS Estima-
tions (GOLPE)
218 a n dG R i da l i g n m e n tI N D e p e n d e n t
(GRIND) approaches have been employed to predict
interaction partners of CYP enzymes. CoMFA as well as
GRID descriptors depend on the alignment of molecules,
which is problematic for many 3D-QSAR applications, as ligand
alignment is nontrivial and time-consuming and induces a bias
into the model. GRID alignment independent descriptors have
been developed to overcome these shortcoming.
219,220 They
are derived from MIFs by a data compression process that
elucidates the most-relevant interaction regions of a molecule.
GRIND descriptors are independent from the orientation of
the molecule and hence only the internal coordinates of
interaction patterns are encoded. Most importantly, GRIND
descriptors can be back-converted into the primary MIF
descriptors by an autocorrelation transform, which allows
visualization and interpretation of data in the original 3D space.
The ALMOND
220 software package allows the calculation,
analysis, and interpretation of GRIND descriptors. It has
recently been superseded by Pentacle.
221
Crivori et al.
222 trained a classification model for the
prediction of the metabolic stability of small organic molecules
to CYP3A4 combining GRIND descriptors with VolSurf, a
MIF-based program to calculate pharmacokinetic properties of
small organic molecules.
223 The training set consisted of 1800
examples from the Pharmacia compound collection. The model
derived using these data obtained a correct prediction rate of
75−85% of the test set compounds, with a precision of 86%
correctly identified metabolically stable compounds. A further study
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224 is
reported in the next section.
CoMFA and GRID/GOLPE regression models were
reported for CYP1A2 inhibition on the basis of a consistently
assembled data set of 52 compounds comprising different
scaffolds.
225 CoMFA models yielded a Q2 of 0.69 (5-fold cross
validation) and R2 of 0.87, GRID/GOLPE yielded a Q2 of 0.79
and R2 of 0.90, respectively. In a similar approach, a CoMFA
model for CYP2B6 inhibition
226 was prospectively validated,
which led to the discovery of three potent pyridine-based novel
CYP2B6 inhibitors. For a CYP2D6 isoform model based on the
CoMFA method, a training set of 24 compounds with reported
Km values was developed which achieved a predictive R2 of 0.62.
CoMFA/GOLPE models were also obtained for 50 steroid
inhibitors of CYP19 (aromatase). The CoMFA fields are
consistent with known, potent inhibitors of aromatase, not
included in the model (R2 of 0.885, cross-validated Q2 of
0.673).
227 In a similar fashion, the CYP2A5 and 2A6 isoforms
were analyzed using CoMFA and GRID/GOLPE.
228 From this
work, it was suggested that the CYP2A5 binding site is likely
larger than that of CYP2A6, as indicated by larger steric regions
in the CoMFA coefficient arrays as well as a similar view of the
corresponding GOLPE maps. From an analysis of electrostatic
maps, it was deduced that CYP2A6 disfavors a negative charge
near the lactone moiety of coumarin, which was in agreement
with available data.
The GRID/GOLPE approach was also successfully employed
to derive a 3D-QSAR model for CYP2C9 inhibitors.
229 In this
study, the selection of ligand conformers was guided by docking
a set of ligands to a CYP2C9 homology model employing
GOLD. Following up on their prior effort, Afzelius et al.
224 used a
more diverse data set to create regression (and classification
models) for CYP2C9 inhibitors. The high diversity of the data,
including ligands of MW 100−1000, rendered the elucidation
of specific alignment rules unfeasible and lead to the application
of a GRIND-based approach using ALMOND. In this study,
74% of the compounds of an external test set could be correctly
classified. A subsequently derived quantitative model was able
to predict the Ki values within half a log unit for the vast
majority of compounds. This work was again extended by
adapting the CORE method developed by Goodford
230 to
handle ligand flexibility in order to account for ligand
movement during the approach to the ligand binding site.
Using this method the relevant conformational space is
encoded in the form of a probability-of-interaction map. The
resulting MIFs were transformed into GRIND descriptor values
using ALMOND. The experimental Ki values of 11 out of 12
compounds representing the external test set were predicted
within half a log unit by this confomer- and alignment-
independent QSAR model.
A further 3D-QSAR study compared the GRID/GOLPE
approach with COMparative BINding Energy (COMBINE)
analysis, an approach that analyses a series of structures of
protein−ligand complexes to derive 3D-QSAR models.
231 It
was found that, provided an appropriate alignment is used for
model generation, that the derived interaction patterns are
largely consistent with each other.
A GRIND-based 3D-pharmacophoric model for CYP3A4
was reported by Cianchetta et al.
232 A data set of 331 com-
pounds with inhibition data available for CYP3A4 was used to
derive a 3D-QSAR model from MIFs. In parallel, GRIND
descriptors were also calculated for four CYP3A4 crystal
structures and subsequently compared with the pharmacophore
model derived from the ligands. A clear correlation between the
3D-QSAR model and the MIFs generated from the
experimental protein structures was found and three features
crucial for binding affinity, two hydrophobic areas and one
hydrogen-bond acceptor, were revealed.
“Classic Pharmacophore-Based Approaches”. Interactions of
ligands with biomolecules are driven by the complementarity of
global and local physicochemical properties. Detection and
analysis of patterns among ligands, the receptor, and ligand−
receptor complexes form the fundamental basis for rational
drug design. A pharmacophore defines a pattern of chemical
and steric features essential for the interaction of a ligand with
its receptor. The robustness of the approach infers from its
simplicity. Only a very few feature types are required to
characterize most of the commonly observed protein−ligand
interaction types, such as hydrogen bond donors/acceptors,
aromatic interactions, hydrophobic interactions, and ionic and
metal interactions. These are usually depicted as colored spheres,
disks, or graphs, and directed features (hydrogen bonding, pi-
stacking and metal binding features) generally include a vector
to indicate their orientations, if determinable.
Classic pharmacophore models are derived in a ligand-based
or structure-based approach. For the ligand-based approach, the
ligands are superimposed on the basis of matching chemically
similar moieties, while for the structure-based approach
analyses of the receptor or receptor−ligand complexes are
used to derive pharmacophore models. In cases where the
target itself or target structure are unknown or not amenable,
ligand-based techniques are typically the only approaches
available.
Development of a pharmacophore model is an iterative
process, attempting to derive the optimum selection of ligands,
chemical features, and geometric constraints during the model
training phase. Rigid templates are particularly favorable for
ligand-based modeling, as they allow the conformational
degrees of freedom to be narrowed down. Once the model
has been validated, large-scale virtual screening is rapid.
Pharmacophore models allow qualitative and quantitative
predictions on the metabolism of small organic molecules. A
pharmacophore model can only cover the chemical space
considered for training of the model and, as a matter of fact,
only a particular binding mode. This is in contrast to protein−
ligand docking, where the protein−ligand interaction motifs are
taken as a global model of the receptor. In general, the
limitation of pharmacophore models to a specific binding mode
is unlikely to affect the applicability of this approach. If
required, multiple pharmacophore models can be constructed
to account for the different interaction patterns. However, in
the case of highly promiscuous binding sites such as in CYP3A4
this may be a limiting factor.
78
Plasticity of the binding site can be reflected in classical
pharmacophore models in part by adjustment of tolerances
surrounding the pharmacophore feature points. For example,
molecular dynamics simulations can be used to quantify and
characterize target flexibility at an atomic level of detail. These
observations can then be included in pharmacophore models
for scoring of the fitness of molecules to the pharmacophoric
constraints.
Reported pharmacophore models have been summarized in a
number of comprehensive reviews,
176,233−237 and therefore,
only a brief overview is presented here.
Qualitative and quantitative pharmacophore models have
been developed for the classification/prediction of substrates
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including CYP1A2, 2A6, 2B6, 2C9, 2D6, 3A4, 3A5, and 3A7.
For example, CYP2D6 includes a characteristic positive charge
about 5−7 Å distant from the oxidation site as well as an
aromatic interaction.
233 Various pharmacophore models were
proposed with respect to the underlying metabolic reac-
tion.
233,236 Most of the CYP2C9 pharmacophore models
include a hydrophobic/aromatic and a negatively charged inter-
action area.
233,238 However, nonanionic substrates of CYP2C9
are known,
239 which illustrates the possibility of bias introduced
into a pharmacophore model by the training data. In contrast to
CYP2C9, 3A4 appears to have no obvious specific pharmaco-
phoric requirements. This isoform has often been reported as
being a particularly challenging target for computational
approaches, but at the same time, it is the most important
CYP for xenobiotic metabolism.
176 Schuster et al.
240 have
reported a collection of eleven structure-based and ligand-based
pharmacophore models for the identification of substrates and
inhibitors binding to various CYP isoforms.
A single pharmacophore model cannot characterize a
promiscuous ligand binding site. Mao et al.
213 have shown
for CYP3A4 that the generation of several local models trained
on distinct data sets performs best.
Overall, pharmacophore-based methods have contributed
significantly to the understanding of CYP ligand binding. They
are powerful, accurate tools for local predictions, driving lead
optimization and rapid prefiltering. Their moderate capabilities
to reflect the global characteristics of promiscuous, highly
plastic interaction sites may limit their applicability in CYP
modeling.
“Protein−Ligand Docking”. Protein−ligand docking can be
used for predicting the binding mode of small organic
molecules to their target as well as providing an estimate of
the binding affinity, although most docking tools estimate the
geometry of binding with a scoring function that is relevant to
only this property and not to binding affinity. The ligand and
protein conformations used as a starting configuration can be
decisive for a docking algorithm.
Docking has also been successfully applied to predict and
rationalize drug−drug interactions on CYP2D6.
241 Twenty
established drugs were investigated for their ability to bind to a
homology model of CYP2D6. Out of the13 drugs predicted to
inhibit this CYP, 11 were experimentally confirmed. In the
course of this study, an aromatic N-hydroxy metabolite of
metoclopramide, a drug to treat nausea and vomiting, was
identified and experimentally confirmed.
Using the same isoform, docking via AutoDock into CYP1A2
homology models has been performed, followed by COMBINE
and GRID/GOLPE analyses of 12 heterocyclic amines. In this
case, it was found that including structural information for the
alignment of compounds did indeed improve model perform-
ance, in agreement with previous findings.
242
“Combined Approaches for Interaction Prediction”. Leong
et al.
243 used a pharmacophore ensemble/SVM approach to
increase the predictive power of a model for CYP2A6 inter-
action. Protein flexibility was simulated by employing three
individual pharmacophore models.
An interesting method employing MIFs is the proteochemo-
metric analysis of CYP sequences to relate these to the activity
of inhibitors.
244 Using this approach, Kontijevskis et al. aimed
to establish a general model for the prediction of isoform-
specific inhibition rates and to gain knowledge about properties
of the different CYP isoforms and their inhibitors. A data set of
375 structurally diverse inhibitors with reported IC50 values for
14 different CYP isoforms was collected and GRIND
descriptors were calculated for all of these small organic
molecules. The protein sequences of 14 CYP isoforms were
aligned and analyzed for characteristic patterns. Six groups of
aligned amino acid positions showed the same variance
throughout the sequence alignment. These groups consist of
two or more amino acid positions with binary sequence
variability, encoded in binary descriptor values. Similar
descriptors were also created for 20 additional amino acid
positions that differed between two amino acids, but without
covariation with any other sequence position. Finally, the
remaining 388 amino acid positions were encoded by five
z-scale properties,
245 which represent principal components for
a set of measured physicochemical properties of amino acids.
Principal component analysis (PCA) was employed to reduce
the number of descriptors for both CYPs and ligands, cross-
terms were generated to describe ligand-CYP interactions, and
PLS was applied for generation of the models. Results of the
model validation indicated a RMSD of prediction of a RMSD of
0.65−0.81 for the prediction of new ligand data on the investi-
gated 14 CYP isoforms. Novel insights into SARs derived from
the MIF-based analysis may help designing drugs with favorable
metabolic profiles. The method could also be used for fast
metabolic profiling in virtual screening.
Bazeley et al.
246 analyzed the binding affinity of substrates of
CYP2D6 using a combination of machine learning, protein
modeling and protein−ligand docking algorithms. Structural
models of various CYPs were aligned and analyzed for
structurally conserved regions, which were conformationally
preserved during subsequent simulated annealing runs. This
resulted in twenty distinct protein conformations reflecting the
flexibility of CYP2D6. 82 small organic molecules with known
affinities for CYP2D6 were docked to these protein
conformations. The docking scores were used as attributes
for ANN model generation. Also compound-specific descrip-
tors were calculated and employed as attributes for model
building. The best performing, optimized ANN model gave a
prediction accuracy of 85%. Attribute selection for the ANN
model identified docking scores of three of the 20 protein
conformations as being dominant for the predictability of
binding affinity. From the ligand perspective, the number of
positive charges, ALogP and the number of aromatic rings were
identified as the most important descriptors.
VirtualToxLab
247 uses a combination of multidimensional
QSAR and flexible docking for the prediction of the
interactions of small organic molecules with 16 antitargets,
including CYP450 1A2, 2A13, 2C9, 2D6, and 3A4. Interactions
of query molecules with any of the 16 target structures can be
visualized.
Predicting CYP Induction by Xenobiotics. CYP induction is
caused by either an amplified de novo synthesis of the protein
or, less frequently, by a decelerated enzyme degradation
pathway.
5 Depending on the CYP isoform involved in DDIs,
enzyme induction can cause minor to substantial clinical
effects.
177 CYP isoforms known to be induced in humans
include CYP1A, 2A, 2B, 2C, 2E1, and 3A.
248
Nuclear receptors are a primary control mechanism for gene
transcription and, hence, a molecule that activates a nuclear
receptor may function as an enzyme inducer. Among the
nuclear receptors most important for the transcription of CYPs
are the aryl hydrocarbon receptor (AhR), constitutive andro-
stane receptor (CAR), and pregnane X receptor (PXR).
5,177
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(XARs). They are known to be highly promiscuous sensors,
binding a set of structurally diverse xenobiotics, in particular
those that are hydrophobic.
182 For example, PXR binds
rifampicin, dexamethasone, bosentan, and artimisinin antima-
larials. Additionally, the peroxisome proliferator activated
receptor (PPAR) and the glucocorticoid receptor (GR) have
also been shown to mediate CYP enzyme expression,
7 and
inducing xenobiotics have been reported to bind to the
hepatocyte nuclear factor-4α (HNF4α) and the vitamin D
receptor.
182 For more detail on xenobiotic inducers of CYPs,
the interested reader is referred to excellent review on modeling
CYP substrates, inhibitors, activators, and inducers by de
Lisle et al.
249
In silico methods have been reported for many of these
receptors but their promiscuity, resulting from their flexibility,
their extended binding pockets and their nonspecific, lipophilic
interaction features make them challenging targets. A number
of in silico methods in particular struggle with the problem of
multiple binding modes for one target. In the case of
pharmacophore models, individual models generally need to
be created for each binding mode.
“Pregnane X Receptor (PXR)”. PXR is one of the key
xenobiotics sensing enzymes regulating the expression of CYP
3A4.
248 It is known for its promiscuity, being able to accommodate
a large range of diverse chemical compounds within the binding
site. Single ligands can be observed to bind in multiple modes,
which adds to the complexity of understanding the binding of
antagonists at this receptor. Xue et al.,
250 who aimed to develop
antagonists by introducing sterically hindering moieties to
known agonists, were unable to find any because of the enormous
promiscuity of this protein.
QSAR studies including a PLS approach in combination with
VolSurf descriptors have been used to derive models for ligands
of human PXR and AhR.
251 Ung et al.
252 employed the
machine learning methods SVM, k-nearest neighbor, and
probabilistic neural network (PNN) for classifying activators
and nonactivators. Prediction accuracy rates for a 10-fold cross
validation test were found in the range of 61−87%, depending
on the compound class (activators and nonactivators).
Also, a number of pharmacophore-based studies have been
reported that aim to derive models identifying compounds
binding to PXR (see refs 253−255). These models in general
include three to five hydrophobic areas as well as one or two
hydrogen bonding features. Yasuda et al.
256 used several
pharmacophore models published in earlier studies to assess
their potential in predicting PXR activators. They found two of
these pharmacophore models obtained reasonable prediction
accuracy, while the model based on the most diverse training
set had inferior performance. This is likely to be caused by the
presence of more than one binding mode, which cannot be
adequately covered by a single model. Intriguingly, dicloxacillin
was found to be the only PXR binder that could be successfully
mapped with any of the three investigated pharmacophore
models. The authors also employed the docking software FlexX
to investigate the binding of known activators to PXR.
Gao et al.
257 introduced new hydrophilic moieties to PXR
activators to lower their activity on this receptor. The optimization
strategies were developed from results of a protein−ligand docking
approach.
In a recently published study assessing the performance and
reliability of PXR, using in vitro assays and in silico modeling
approaches, the physicochemical properties of 37 marketed
drugs and their interaction with PXR were examined.
258 The
computational analyses pointed out that descriptors for
molecular weight and shape of a ligand are decisive for its
potential to bind to PXR. Compounds of molecular weight
lower than 300 as well as compounds that have a molecular
shape which does not correspond to the inverse shape of the
protein binding site are unlikely to exhibit activity. Strong
binders show favorable hydrophobic interactions and hydrogen
bonding features within the binding pocket, as observed during
docking studies using GLIDE.
53 Binding promiscuity is
facilitated by the flexibility of the protein but also by the
conformational space accessible to the binders.
“Aryl Hydrocarbon Receptor (AhR)”. AhR is a cytosolic transcrip-
tion factor that is a key regulator for CYP1A1 and CYP1A2 in
humans.
248 Besides the induction of these CYP isoforms, AhR
signaling also induces a number of other enzymes including
UDP-glucuronosyltransferase 1A (UGT1A1) and glutathione
S-transferase A2 (GSTA2).
In addition to the QSAR models for human AhR and PXR
presented above, recent examples include the work of Bisson
et al.,
259 who derived homology models of the AhR PAS domain
to investigate intraspecies and interspecies differences in ligand
binding using Internal Coordinate Modeling (ICM).
260 Among
other observations, their approach led to the successful
identification of two flavonoids, pinocembrin and 5-hydroxy-
7-methoxyflavone, which are experimentally shown to be
promoters of nuclear translocation and transcriptional
activation of AhR and AhR-dependent induction of endoge-
nous target genes. As an example of an implementation in a
commercial software product, a model for the prediction of
ligand activity on AhR is included in VirtualToxLab.
“Constitutive Androstane Receptor (CAR)”. The constitutive
androstane receptor (CAR) is responsible for the induction of
CYP2B6, which is a key enzyme for the metabolism of a large
number of drugs including human immunodeficiency virus
(HIV) therapeutics, chemotherapeutics and opioids.
248
Using a pharmacophore-based approach, CAR ligands were
reported to show planar structures with a hydrogen bond
acceptor and two to three hydrophobic areas.
261 Jyrkkärinne
et al.
262 used pharmacophore-based virtual screening to identify
novel agonists of CAR and employed these data to develop a
GRID/GOLPE-based 3D-QSAR model in an attempt to
explain activity of compounds on CAR. For a leave-20%-out
validation method, the model obtained a Q2 value of 0.68 and a
standard error of prediction of 0.93. Further to that, docking
studies of CAR agonists on the X-ray structure of human CAR
revealed several key interactions for ligand binding.
More recently, homology models derived for CAR, AhR, and
PXR (all in the rat) were used as a structural basis for docking a
number of organic pollutants such as polybrominated
dibenzofurans and polybrominated diphenyl ethers to these
nuclear hormone receptors, with the aim of identifying
potential binders to these proteins.
263 The results of this
retrospective study were found to be in agreement with results
of experiments and suggest that such structure-based modeling
methods represent valuable tools for the evaluation of effects of
small organic molecules on nuclear hormone receptors.
■ PERSPECTIVE AND OUTLOOK
Metabolic properties are decisive for the discovery, develop-
ment, and market success of drugs, nutritional supplements,
and agrochemicals. Interactions of xenobiotics with key
metabolizing enzymes may lead to considerable changes in
Journal of Chemical Information and Modeling Perspective
dx.doi.org/10.1021/ci200542m | J. Chem. Inf. Model. 2012, 52, 617−648 639kinetics, which may cause toxic effects or failure of action.
Genetic polymorphism adds another layer of complexity to the
problem.
Numerous drug candidates and agrochemicals have failed in
the past and novel entities are still failing because of
unfavorable metabolic profiles, despite substantial efforts
being made in industry to predict such problems early and to
develop strategies to counter them.
A plethora of computational methods, both ligand-based and
structure-based, have been developed, which can provide
decisive insights on the metabolic fate of xenobiotics. They
allow the prediction of likely sites of metabolism (SOMs), the
chemical structure of potential metabolites, and inhibition and
induction of key enzymes involved in xenobiotic metabolism.
For all of these areas of research, a number of success stories
have been published, as discussed in this review.
The complexity of predicting xenobiotic metabolism suggests
that one particular algorithm will not show superior perform-
ance in all of the three domains discussed here. Rather, the
combination of techniques is most promising to lead to valid
conclusions.
SOM prediction is feasible, with state-of-the-art computa-
tional methods successfully identifying SOMs among the three
highest-ranked atom positions in a range of 70−90% for most
cases. Even though relative ranking of atom positions is feasible,
current methods do not make accurate predictions for the
absolute likelihood of a certain biotransformation. This
limitation makes it difficult if not impossible to draw any
quantitative conclusions on the metabolic liability of a certain
molecule and, hence, to compare different molecules with
respect to their metabolic stability. In particular, the
combination of individual methods covering different aspects
of the biotransformation process could be expected to lead to a
potential boost in prediction accuracy. Systems biology
approaches (not reviewed here) have a major contribution to
make by incorporation of multiple models that take into
account not only the likelihood of metabolism at a site in a
molecule at a specified rate but also the molecules
bioavailability and concentration at the tissue site of
metabolism. A much more complicated scenario.
Knowledge-driven approaches such as expert systems and
data mining techniques allow extrapolation of the structure to
likely metabolites. Most challenging in this domain is
addressing the combinatorial explosion problem, which arises
from the virtually unlimited possibilities for processing
generations of metabolites. Advanced reasoning rules and
knowledge-based potentials considered for metabolite ranking,
as well as consideration of physicochemical properties of the
generated metabolites (such as logP) attempt to address this
problem as well as possible.
Also, a respectable number of computational approaches
have been developed and applied to the prediction of direct and
indirect interactions of xenobiotics with key metabolic enzymes.
CYPs represent the primary focus of research and inhibition of
this enzyme family has been successfully predicted by a variety
of computational approaches including (3D)-QSAR and
machine learning methods, pharmacophore- and docking-
based approaches, as well as combinations of these. The
expression of CYPs is steered by nuclear receptors such as PXR,
AhR, and CAR, to which similar methodologies have been
applied but to a lower extent.
Methods developed in academia all too often lack maturation
of the promising concepts they are based upon or an implementation
of these algorithms into accessiblein the best caseuser-friendly
software packages. Tools freely available to the scientific com-
munity are still scarce. Further, the limited data related to meta-
bolism (experimentally derived SOMs, structures of metabo-
lites, enzyme inhibition, and induction data) are a bottleneck
for method development. However, recent major releases of
bioactivity data to the public, such as ChEMBL,
264 World Of
Molecular BioAcTivity (WOMBAT),
265 and others,
199 give
promising indications of a paradigm shift in the scientific
community, fostering the open publication of experimental
data.
Also with regard to structure-based approaches, there is still
enormous potential left for further development. Even though
several crystal structures of a variety of CYPs have become
available, their numbers are not sufficient to adequately
represent, in particular, flexibility of the enzyme catalytic site,
though homology modeling and MD simulation techniques can
help to overcome some of these limitations. For instance, for
the development of agrochemicals it would be of utmost
importance to have structures available of pest species.
Expeditious technological progress in structure determination
will improve this situation in the future and make enzyme-
focused methods other than CYPs even more powerful and
important. An improved data situation will also contribute to
solving cardinal problems of structure-based approaches, such
as target flexibility (in particular for CYPs), solvent, entropic
effects, and as a consequence, affinity and rate of reaction
prediction.
However, it is not expected that computational methods will
substitute in vitro and in vivo methods in the foreseeable future.
In fact, it is crucial for the generation of computational models
to be based on further enhanced assay technology. Computa-
tional methods are still limited by the reliability of assay systems
and the information content of the read out.
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■ ABBREVIATIONS
ADME = absorption, distribution, metabolism, and excretion
AhR = aryl hydrocarbon receptor
AMBER = Assisted Model Building with Energy Refinement
ANN = artificial neural network
ANNC = artificial neural network classification
ANNE = artificial neural network ensemble
CAR = constitutive androstane receptor
CHARMM = Chemistry at HARvard Molecular Mechanics
COMBINE = COMparative BINding Energy
CoMFA = Comparative Molecular Field Analysis
CYP = cytochrome P450
DDI = drug−drug interaction
DFT = density functional theory
EPR = electron paramagnetic resonance
FEP = free energy perturbation
FF = force field
GLIDE = Grid-based LIgand Docking with Energetics
Journal of Chemical Information and Modeling Perspective
dx.doi.org/10.1021/ci200542m | J. Chem. Inf. Model. 2012, 52, 617−648 640GRIND = GRid alignment INDependent
GOLD = Genetic Optimization for Ligand Docking
GOLPE = Generating Optimal Linear PLS Estimations
GSTA2 = glutathione S-transferase A2
HIV = human immunodeficiency virus
ICM = Internal Coordinate Modeling
KEGG = Kyoto Encyclopedia of Genes and Genomes
k-NN = k-nearest neighbor
LC = liquid chromatography
LIE = linear interaction energy
MAO = monoamine oxidase
MC = Monte Carlo
MD = molecular dynamics
MDEA = (R)-3,4-methylenedioxy-N-ethylamphetamine
MIF = molecular interaction field
ML = machine learning
MM = molecular mechanics
MS = mass spectrometry
NADPH = nicotinamide adenine dinucleotide phosphate
NCE = novel chemical entity
NCGC = National Institutes of Health Chemical Genomics
Center
OECD = Organisation for Economic Co-operation and
Development
PCA = principal component analysis
PLOP = Protein Local Optimization Program
PLS = partial least-squares
PME = Particle Mesh Ewald
PNN = probabilistic neural network
PXR = pregnane X receptor
QM = quantum mechanics
QM/MM = quantum mechanics/molecular mechanics
QSAR = quantitative structure−activity relationship
RAMBA = retinoic acid metabolizing blocking agent
RMSD = root-mean-square deviation
RMSF = root-mean-square fluctuation
ROC = receiver operating characteristic
ROCS = rapid overlay of chemical structures
RS-predictor = RegioSelectivity predictor
SAR = structure−activity relationship
SASA = solvent-accessible surface area
SMARTS = SMiles ARbitrary Target Specification
SOM = site of metabolism
SVM = support vector machine
SyGMa = Systematic Generation of potential Metabolites
TI = thermodynamic integration
TIMES = TImes MEtabolism Simulator
UGT1A1 = UDP-glucuronosyltransferase 1A
UM-BBD = University of Minnesota Biocatalysis/Biode-
gradation Database
UM-PPS = University of Minnesota Pathway Prediction
System
WOMBAT = World Of Molecular BioAcTivity
XAR = xenobiotic-activated receptor
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